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91 Many full-length proteins and protein regions lack stable
92 tertiary and/or secondary structure under physiological
93 conditions in vitro. These proteins and regions, known as
94 intrinsically disordered (ID) proteins (IDPs) and ID protein
95regions (IDPRs), have attracted signiﬁcant attention from
96researchers over the past decade and a half.1−34 Proteins with
97disorder are highly abundant in nature, with ∼25−30% of
98eukaryotic proteins being mostly disordered, and with >50% of
99eukaryotic proteins and >70% of signaling proteins having long
100disordered regions.35−39 Functionally, IDPs/IDPRs comple-
101ment the functions of ordered proteins and domains, being
102often involved in regulation, signaling, and control path-
103ways.1,3,5−7,14,15,19,24−28,33 IDPs and IDPRs are the key players
104in various protein−protein interaction networks, being
105especially abundant among hub proteins and their binding
106partners.14,40−44 Functions of IDPs/IDPRs may arise from a
107speciﬁc disordered form, from interconversion between
108disordered forms, and from transitions between disordered
109and ordered states.3,4,9,10,33 The choice between these states is
110determined by the speciﬁc protein environment. Many IDPs
111possess an exceptional ability to fold in a template-dependent
112manner, where a single IDPR can bind to multiple partners
113gaining very diﬀerent structures in the bound state.28,45 IDPRs
Figure 1. Diﬀerent classiﬁcation types of protein−protein complexes. (A) Composition and geometry-based classiﬁcations. Complexes can be
assembled from identical (a) and diﬀerent subunits (b). Diﬀerent types of monomers are shown by diﬀerent shades of yellow and blue colors.
Interactions leading to homo-oligomers are shown by arrows of the corresponding color. Interactions leading to the hetero-oligomers are shown by
green arrows. Homodimers associate isologously. Interfaces of the dimers located at the center of homotetramers are also formed isologously,
whereas all of the interfaces in the hetero-oligomers and the interfaces formed between the central homodimers and side-added monomers are
formed heterologously. (B) Lifetime-based classiﬁcation of oligomers. Complexes can be of transient (a), permanent nonobligate (b), or permanent
obligate (c) nature. Formation of the permanent obligate complex is accompanied by the global folding of protomers. Hero-dimers and homologous
transitions are shown for simplicity. (C) Folding-based classiﬁcation. Protein complexes can be formed in a three-state mechanism (a), where protein
folding and binding happen as two independent and subsequent steps. Alternatively, some proteins are formed in a two-state manner (b), where
folding and binding occur simultaneously. (D) The per-residue surface area versus the per-residue interface area plot to discriminate between the
three-state and two-state complexes. Here, the results of the computational disassembly of the eukaryotic ribosome (PDB ID: 3U5C and 3U5E)508
are shown. Surface and interface area normalized by the number of residues in each chain for the ribosomal proteins were estimated as described in
ref 64. Proteins of the 40S and 60S subunits are shown by red and blue circles, respectively. A boundary separating ordered and disordered
complexes is shown as a black dashed line.
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114 provide excessively large, malleable binding surfaces,15 which
115 can associate with promiscuous partners resulting in distinct,
116 even opposite functions.18 IDPs/IDPRs carry out molecular
117 recognition either in a binding-coupled folding process,5 or via
118 short segment(s) embedded in a highly variable region.46 These
119 short segments, often termed as molecular recognition features
120 (MoRFs)47 or the related eukaryotic linear motifs,48 are
121 distinguished in protein−protein interactions.49
122 It is recognized now that IDPs and hybrid proteins with long
123 IDPRS can adopt a continuum of structural states, such as
124 completely disordered, molten globules, or locally disordered
125 tails and linkers.2,15,50 This variety of disordered states can be
126 beneﬁcial, even prerequisite for various biological roles.4,6,8,17,21
127 In fact, IDPRs can act as entropic chains (linkers, clocks,
128 bristles) as the Nup2p FG repeat region of the nuclear pore
129 complex for example is responsible for regulation of gating.51
130 They often serve as target sites for post-translational
131 modiﬁcations (display sites), such as the KID domain of
132 CREB, the phosphorylation of which induces its binding to the
133 KIX domain of CBP.52 Binding of IDPs/IDPRs can also
134 modulate the eﬀect of the partner (eﬀectors). For example,
135 p27Kip1 regulates cell-cycle by binding to cyclin-dependent
136 kinases and inhibiting their activity.53 Intriguingly, their
137 malleability enables binding in diﬀerent conformations leading
138 to unrelated, even opposite functions.18 Activation and
139 inhibition of the ryanodine receptor can be eﬀected by the
140 binding of the same disordered C-terminal region of the
141 dihydropiridine receptor (DHPR) in two diﬀerent conforma-
142 tions.54 IDPs/IDPRs frequently participate in folding of
143 proteins (e.g., heat-shock proteins, Hsps, and other protein
144 chaperones)55,56 or RNA partly by holding under-folded forms
145 or by unfolding the incorrect structures and facilitating
146 formation of new contacts (chaperones).12 Formation of the
147 scrapie form of prions is critically dependent on the transient
148 disordered state.57 Large multiprotein complexes also take
149 advantage of IDPs that assist assembly of these organizations
150 (assemblers). The RNA polymerase II disordered C-terminal
151 domain provides a platform for the mRNA processing
152 machinery.58 Alternatively, IDPs/IDPRs can capture and store
153 small ligands (scavengers). This underlies the response to
154 dehydration stress in plants achieved by water retention by
155 Desiccation stress protein (Dsp) 16.59 IDPs/IDPRs are very
156 promiscuous binders and are constantly involved in various
157 interactions with diverse partners.60,61
158 Intrinsic disorder is abundant in proteins involved in
159 signaling and regulatory processes, where disorder-mediated
160 protein interactions enable transient signaling complexes. On
161 the other hand, intrinsic disorder provides various beneﬁts for
162 organization of large protein assemblages. In addition to the
163 transient signaling complexes, there are numerous stable
164 protein complexes (oligomers) that represent a functional
165 form of proteinaceous machines. Functional disorder could be
166 two distinctive types: (i) internal for assembly and movement
167 of the diﬀerent parts and (ii) external for interaction with
168 regulators. The goal of this Review is to show that intrinsic
169 disorder impacts the function and assembly of the proteina-
170 ceous machines. The ﬁrst half of this Review considers some
171 general aspects related to the involvement of intrinsic disorder
172 in assembly and function of the protein complexes, whereas the
173 second half is dedicated to the representation of some
174 illustrative examples of pliable proteinaceous machines.
2. INTRINSIC DISORDER AS A CRUCIAL FACTOR FOR
175THE ASSEMBLY OF PROTEIN COMPLEXES
2.1. Starting Simple: Forming Ordered Oligomers Out of
176Disordered Subunits
177Many biological functions are performed by oligomeric proteins
178consisting of two or more polypeptide chains. Similar to a
179journey of a thousand miles that begins with a single step,
180formation of the most sophisticated protein complexes begins
181with the dimer formation. Some basic principles underlying
182productive protein−protein interactions are rather well under-
183stood,62−64 and in addition to their complexity (which is
184deﬁned by the oligomerization degree) protein complexes are
185classiﬁed on the basis of their compositions, geometrical
186considerations, lifetimes, obligatoriness, and the disorderedness
187of the unbound forms, which is linked to the molecular
188 f1mechanisms of a given complex formation. Figure 1 represents
189some of the classiﬁcations of protein−protein complexes
190discussed below.
191Composition-based classiﬁcation takes into account a simple
192fact that the polypeptide chains involved in the complex
193formation can be identical or nonidentical, thereby giving raise
194to homo- and hetero-oligomers (Figure 1A). Geometrically,
195units of the homo-oligomers can be organized isologously or
196heterologously,65,66 where isologous association involves the
197same surface on both monomers of the homo-oligomer, and an
198heterologous association relies on diﬀerent interfaces (Figure
1991A).63
200From the viewpoint of their lifetimes, protein complexes can
201be classiﬁed as transient (where protein−protein interactions
202are easily formed and destroyed leading to transient association
203and dissociation) and permanent (where protein−protein
204interactions are usually very stable and the protomers only
205exist in the complexed form) (Figure 1B). Also, some
206complexes are obligate, with their protomers being not found
207as stable structures on their own, whereas other complexes are
208nonobligate, whose protomers can exist independently of the
209complex. Although the terms “obligate” and “permanent”
210describe the same phenomenon (the obligate interactions are
211typically permanent), “non-obligate” and “transient” are not
212synonymous terms, because nonobligate interactions can lead
213to the formation of both transient and permanent complexes.63
214This is further illustrated by Figure 1B, which shows that
215complexes can be transient, permanent nonobligate, or
216permanent obligate. Furthermore, transient and permanent
217interactions can be distinguished from the evolutionary
218viewpoint, with stable/permanent interactions being highly
219conserved, and with transient/temporary interactions being
220typically less conserved.67
221Mechanistic classiﬁcation is based on the notion that the
222dimers and trimers were observed to fold through two major
223paradigms: two-state and three-state mechanisms.64,68,69 Here,
224protomers forming the two-state (or disordered) complexes are
225disordered in their unbound forms and fold at the complex
226formation (see Figure 1C, right side). This behavior is diﬀerent
227from the formation of the so-called three-state (or ordered)
228complexes, individual chains of which are independently folded
229into a stable structures even in their unbound states, with a
230subsequent oligomerization (see Figure 1C, left side).68,69 It
231was also emphasized that many complexes and protein−protein
232interactions cannot be easily classiﬁed into speciﬁc rigidly
233deﬁned classes, and, instead, a continuum exists between
234transient and permanent, and nonobligate and obligate
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235 interactions, because the stabilities of all complexes are strongly
236 dependent on the peculiarities of the environment.63 The same
237 concern is also applicable to the classiﬁcation based on the
238 molecular mechanisms of complex formation. In fact, among
239 these mechanisms are two extreme cases known as a
240 conformational selection model and an induced ﬁt (or induced
241 folding) model, which are also applicable for the description of
242 the peculiarities of protein interaction with small mole-
243 cules.70−74 The conformational selection model suggests that
244 the protein exists in a dynamic equilibrium between major and
245 minor species, and the binding partner selectively interacts with
246 the minor species leading to the formation of the protein−
247 ligand complex. The induced ﬁt model assumes that the
248 binding partner interacts with the major species followed by a
249 conformational change in the initial (weak) complex eventually
250 resulting in the formation of the ﬁnal protein−ligand complex.
251 It was emphasized that these two pathways can potentially be
252 distinguished by transient kinetic measurements, and that, for a
253 given complex, both mechanisms may be operational, with the
254 preferred reaction path being modulated by the protein and
255 ligand concentrations.71,74 It is also important to remember that
256 these two mechanisms represent extreme models for the
257 possible mechanisms of complex formation, and that the reality
258 is likely to involve sequential combination of both mechanisms.
259 Coming back to the molecular mechanisms of the protein
260 complex formation, the noted separation of oligomers (mostly
261 dimers and trimers) to the two-state and three-state multimers
262 is very important from the viewpoint of this Review. In fact,
263 monomers of oligomers that are formed via a two-state
264 mechanism are intrinsically disordered in their uncomplexed
265 form and clearly undergo the binding-induced folding at the
266 complex formation. Curiously, careful analysis of the structural
267 characteristics of the two-state and three-state multimers
268 revealed that the per-residue interface and surface areas of
269 ordered protomers forming the three-state oligomers are
270 signiﬁcantly smaller than those of the disordered monomers
271 forming the two-state multimers.64 As a result, in the per-
272 residue surface area versus the per-residue interface area plot,
273 the two-state and three-state complexes occupy very diﬀerent
274 areas, with the disordered proteins (that form complexes in a
275 two-state mechanism) being distributed sparsely over a broad
276 area in the top-right part of the plot, suggesting that disordered
277 proteins opt for extended shapes and larger interface areas, and
278 with ordered proteins (that form complexes in a three-state
279 mechanism) being condensed in the small area at the bottom-
280 right corner of the plot, suggesting that these proteins are more
281 globular and compact in their bound form.64 Furthermore, it
282 was also pointed out that because the maxima of per-residue
283 surface and interface areas for stable monomers lie around 80
284 Å2, the line connecting these two extreme values in the per-
285 residue surface area versus the per-residue interface area plot
286 represents a natural boundary separating ordered and
287 disordered proteins forming three-state and two-state com-
288 plexes, respectively.64 Here, ordered proteins were systemati-
289 cally located below this boundary, and the disordered proteins
290 were widely spread above the boundary.64 Importantly, this plot
291 (example of which is shown in Figure 1D) provides a simple
292 scale that measures the conﬁdence with which a conclusion can
293 be made of whether a given protein in its bound form can (or
294 cannot) exist as a stable monomer.64 One should keep in mind
295 though that this approach represents an elegant and eﬃcient
296 tool to assess independent foldability of a protein taken out of a
297 complex and cannot reveal the subtle kinetic and structural
298diﬀerences between the conformational selection and induced
299ﬁt scenarios of molecular recognition.
2.2. Stepwise Targeting and Assembly: Binding Chain
300Reactions
3012.2.1. Stepwise Targeting and Binding to “Hidden”
302Sites. It is generally assumed that the recognition and binding
303by IDPs/IDPRs involves their folding into a speciﬁc
304structure,3,4,9,10,33,75−80 and that advantages of IDP/IDPR as
305signaling hubs are their adaptability, promiscuity, and ability to
306fold diﬀerently upon binding to diﬀerent targets.28,45 Another
307functional advantage of the disordered binders has been
308recently recognized, the ability for a stepwise target recognition
309due to the multiform binding eﬀect.80 This hypothesis is based
310on the notion that all of the interaction sites are exposed
311outside of the target molecule and easily accessible to the IDP.
312As a result, some IDP−target complexes are formed in a
313stepwise manner, where intermediate states are observed in the
314binding processes. Formation of such binding intermediates
315results in the structural changes in a partner molecule leading to
316the exposure of its “hidden” binding site, which can be accessed
317by an IDP due to its structural ﬂexibility.80 Shirai and Kikuchi
318analyzed this possibility computationally by ﬁrst building a
319lattice model of an IDP based on the extended HP
320(hydrophobic-polar) model, where an IDP is represented as
321chain with a mixture of various conformations without a speciﬁc
322structure formed in an equilibrium state, and where the target is
323modeled as a highly coarse-grained object designed as a
324combination of plates, which represent the binding surface with
325motions present on both sides of the target to open or close the
326binding surface. Next, computational simulations of this model
327were used to study the target recognition process.80 This model
328was able to reproduce the stepwise recognition, where
329intermediates or encounter complexes formed early in the
330recognition process providing the ﬁrst scaﬀold to open one side
331of the hidden binding sites followed by the IDP interaction
332with the surface to stabilize the second scaﬀold to access the
333other hidden binding sites.80 The authors concluded that the
334presence of binding intermediate states represents a character-
335istic feature of IDP binding to targets with “hidden” binding
336sites.80
337 f2Figure 2 represents two models illustrating binding between
338an IDP and an ordered partner with a “hidden” binding site.
339Figure 2A shows, in an oversimpliﬁed way, that the formation
340of the binding intermediate is a necessary step needed for
341productive waiting for the opening of the originally closed
342binding site. Figure 2B represents a more complex model with
343two sequential binding intermediates, where the formation of a
344second intermediate stabilizes the open state of the partner,
345thereby providing means for an easy access to the originally
346hidden binding site. In both cases, the hidden binding site can
347be open spontaneously or as a result of allosteric interaction.
348Obviously, more complex mechanisms are possible.
349Curiously, the presence of binding intermediates was
350reported for signaling recognition reaction of several IDPs,
351the targets of which are characterized by the presence of hidden
352binding sites, that is, sites that are not exposed outside of the
353target molecule and are not easily accessible to IDP. The two
354related examples are the formation of the p27Kip1/cyclin A/
355cyclin-dependent kinase 2 (Cdk2) complex53,81 and the pKID−
356KIX interaction.77 Here, an intrinsically disordered p27 binds to
357the binary cyclin A−Cdk2 complex in a stepwise manner, ﬁrst
358by interacting with a groove of the cyclin A and then via
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359 binding to the hydrophobic interaction sites Cdk2 had
360 originally hidden from interaction.82 In another example, an
361 intrinsically disordered kinase inducible activation domain
362 (pKID) of the transcription factor cyclic-AMP-response-
363 element-binding protein (CREB), being phosphorylated,
364 forms an intermediate binding complex with the ordered
365 partner, the KID-binding (KIX) domain of CREB binding
366 protein. In this intermediate complex, the buried interaction
367 site of the KIX is not completely exposed and does not properly
368 interact with pKID, whereas in the ﬁnal bound state, pKID
369 inserts one of its hydrophobic residues deeply into the buried
370 interaction pocket of KIX.77
371 2.2.2. Stepwise Assembly of SNARE Complex. An
372 illustrative example with well-documented stepwise assembly of
373 a multiprotein is given by the assembly of soluble N-
374 ethylmaleimide-sensitive factor attachment protein receptor
375 (SNARE) complex, which is a molecular engine that drives
376 membrane fusion.83,84 In fact, SNARE plays a crucial role in the
377 vesicle fusion in eukaryotes by cross-linking the fusing
378 membranes through the transmembrane domains of the
379 corresponding proteins. In neurons, ternary SNARE complexes
380 consist of syntaxin, synaptobrevin, and synaptosome-associated
381 protein of 25 kDa (SNAP-25) on deposited lipid bilayers.85
382 Here, a binary complex t-SNAREs between syntaxin and
383 SNAP-25 is present on the target plasma membrane, whereas
384 the vesicle membrane contains v-SNAREs (synaptobrevin, also
385 called VAMP2).86 Although individual t- and v-SNAREs are
386 largely disordered, they mediate membrane fusion via binding-
387 induced folding resulting in the formation of an extraordinarily
388 stable zipper-like four-helix bundle that draws two membranes
389 into close proximity for fusion.87−89
390 Analysis of the preassembled neuronal SNARE complexes by
391 intermolecular single-molecule ﬂuorescence resonance energy
392 transfer (smFRET) revealed that they represent a mixture of
393 parallel and antiparallel conﬁgurations involving the SNARE
394 motifs of syntaxin and synaptobrevin and the SNARE motifs of
395 syntaxin and SNAP-25.85 smFRET analysis also revealed that
396 the syntaxin/SNAP-25 interactions precede assembly of the
397 ternary SNARE complex.90 Furthermore, the syntaxin/SNAP-
398 25 binary complex was shown to undergo structural transitions
399 between several states, with one state representing a parallel
400 three-helix bundle and the other states characterized by
401dissociation of one of the SNAP-25 SNARE domains. The
402transition between these states happened on the second time
403scale, and the formation of the dissociated helix states was
404eﬃciently suppressed by adding synaptobrevin or accessory
405proteins, such as complexin, Munc13, Munc18, or synapto-
406tagmin.90 Stepwise disassembly of the SNARE complexes was
407also demonstrated by optical tweezers.89,91
4082.2.3. Directional Sequential Assembly: Binding Chain
409Reaction Model. Obviously, the described above stepwise
410binding mechanism, where intrinsic disorder of some proteins
411allows them to interact with hidden binding sites of ordered
412partners, represents a special case of a more general allosteric
413mechanism, where the complex formation between an IDP and
414its target leads to conformational changes in a target and
415opening of a hidden binding site. Alternatively, binding-induced
416(partial) folding of an IDP can generate a new conformation
417with a novel binding site. Therefore, binding chain reactions
418can occur, in which interaction between proteins A and B
419induces structural changes in B or/and A, leading to the
420creation of new binding site(s) necessary for the additional
421interactions between A and B and to the strengthening of the
422AB complex. Alternatively, an activated AB* complex is created,
423where some novel binding sites are present providing the AB*
424complex with the capability to interact with a new partner C.
425When an ABC complex is formed, mutual rearrangements take
426place, new binding sites are created, and the activated ABC*
427complex is now ready to interact with a new partner D.
428Obviously, the stepwise recognition and binding might be the
429mechanism that deﬁnes the timing and speciﬁc order of the
430assembly of some complexes, for example, where C cannot
431 f3interact with A until AB complex is formed (see Figure 3). It
432was pointed out that the phenotypes resulting from mutations
433in components of the complex can be deﬁned by the speciﬁc
434assembly order of protein complexes, where a mutation in one
435protein of a complex could result in accumulation of an
436assembly intermediate maintaining residual function or deﬁning
437a gain of function, whereas a diﬀerent assembly order could
438result in a complete lack of assembly and a total loss of
439function.92
Figure 2. Two models illustrating binding between an IDP and an
ordered partner with a “hidden” binding site. (A) A simple model of
interaction with one binding intermediate. (B) A more complex model
with two sequential binding intermediates.
Figure 3. Model of the binding chain reaction. See explanations in the
text.
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440 An illustrative example of the discussed above stepwise
441 directional mechanism of complex formation is given by
442 BBSome, a stable Bardet−Biedl syndrome (BBS) protein
443 complex.92 BBS is a complex disease characterized by the
444 combined symptoms of obesity, retinal degeneration, poly-
445 dactyly, kidney abnormalities, cognitive impairment, hyper-
446 tension, and diabetes.93,94 There are 16 BBS-associated genes,95
447 with seven proteins (BBS1, 2, 4, 5, 7, 8, and 9) being involved
448 in the formation of BBSome, a speciﬁc complex known to be
449 involved in membrane traﬃcking to and inside the primary
450 cilium, ciliary membrane biogenesis via the small GTPase Rab8
451 and its interacting protein, Rabin8,96 and regulation of the
452 hedgehog signal transduction.97 Furthermore, BBS1, BBS2,
453 BBS4, BBS7, BBS8, and BBS9 contain multiple protein−
454 protein interaction domains. Furthermore, three BBS proteins,
455 BBS6, BBS10, and BBS12, are chaperones that interact with
456 CCT/TRiC proteins and BBS7 to form a BBS−chaperonin
457 complex that plays a role in BBS7 stability.92 On the basis of the
458 careful mutational analysis, the directional and ordered nature
459 of the BBSome formation has been revealed. Here, BBS7
460 interacts with BBS2 and becomes part of the BBS7−BBS2−
461 BBS9 assembly intermediate, the BBSome core, to which BBS1,
462 BBS5, BBS8, and ﬁnally BBS4 are sequentially added to form
463 the complete BBSome.92 A directional mechanism has been
464 also described for the formation of some other large complexes,
465 such as the mammalian 20S proteasome,98 the intraﬂagellar
466 transport complex,99 and various ribonucleoprotein com-
467 plexes,100 such as 60S ribosomal subunits.101
468 2.2.4. Role of Intrinsic Disorder in the Directional
469 Assembly. Another interesting twist came from the analysis of
470 assembly and disassembly of protein complexes with electro-
471 spray mass spectrometry that helped with identiﬁcation of the
472 intermediate subcomplexes present at each step of assembly
473 and disassembly.102 First, on the basis of the analysis of simple
474 homo-oligomers, it has been concluded that some simple
475 features of the known crystal structures can be used for the
476 eﬃcient prediction of the identities of the assembly
477 intermediates, where at each disassembly step the largest
478 interfaces would be preserved and smaller interfaces broken.103
479 Later studies of the more complex hetero-oligomers supported
480 this observation and revealed that disassociation of a complex
481 always occurs in such a way that the least amount of buried
482 interface area is exposed.104−106 Reversely, the assembly of a
483 complex should preferentially start with the formation of a
484 subcomplex with the largest interface. Because the per-residue
485 interface and surface areas of ordered proteins forming the
486 three-state oligomers are signiﬁcantly smaller than those of the
487 disordered monomers forming the two-state multimers,64 this
488 fact clearly suggests that two-state subcomplexes will be formed
489 ﬁrst. In other words, the very ﬁrst step in the formation of a
490 complex involves binding-induced folding of some important
491 IDPRs, which is followed by the formation of complexes with
492 small interface areas (i.e., the interactions between the
493 prefolded components). This order of events makes perfect
494 sense, because the binding-induced folding needed for the
495 formation of the two-state subcomplexes at the early stages of
496 the multimer assembly will undoubtedly generate more ordered
497 species, which will have their binding sites created as a result of
498 the subcomplex formation. In other words, for the complexes
499 containing both large and small interfaces, the folding-driven
500 association leading to the formation of the two-state
501 subcomplexes is the necessary prerequisite for the subsequent
502 formation of the three-state ordered subcomplexes.
2.3. Allostery of the Disorder-Based Interactions
503Allosteric regulation is driven by binding of an eﬀector
504molecule to an allosteric site, that is, to a site topographically
505distinct from the protein active site. To this end, an allosteric
506protein has at least two identical or diﬀerent ligands, the
507binding of one of which modulates the aﬃnity of the protein
508toward the second ligand.107 Therefore, an allosteric protein is
509a modular multifunctional protein that can be considered as a
510group of interacting domains,108 with the binding sites for
511diﬀerent ligands being segregated into the diﬀerent structural
512domains.109 The two binding sites may be on the same
513polypeptide chain although in diﬀerent domains, or in diﬀerent
514subunits.107 Allostery explains protein action via coupling of
515conformational changes between two widely separated sites.107
516This coupling can be described by the concerted or symmetry
517model proposed by Monod, Wyman, and Changeux (so-called
518MWC model),65 or by the sequential model proposed by
519Koshland, Nemethy, and Filmer (KNF model).110 Both of
520these models suggest that the subunits of an allosteric protein
521can exist in two conformations, tense (T) and relaxed (R),
522where relaxed subunits interact easier with the eﬀector
523molecule than the tense subunits. According to the MWC
524model, the equilibrium favors one of the conformational states,
525T or R. All subunits exist in the same conformation, being
526connected in a special way that ensures that a conformational
527change in one subunit is conferred to all other subunits. As a
528result, the protein interconverts between R and T conforma-
529tions in a concerted manner and cannot exist in a hybrid TR
530form.65 In the sequential or KNF model, subunits can change
531conformation one at a time. They need not exist in the same
532conformation, and conformational changes are not propagated
533to all subunits, thereby providing the possibility for a hybrid TR
534form to occur.110 KNF model also suggests that eﬀectors bind
535to a protein via the induced-ﬁt scenario, where the initial
536interaction between enzyme and substrate is relatively weak,
537but that these weak interactions rapidly induce conformational
538changes in the protein that strengthen binding.110 Later, MWC
539and KNF models were combined to a general model of
540allostery.111
541It has been believed that allostery refers to the situations
542where the binding of a ligand to one site can aﬀect the other
543through a propagated change in the protein shape. However,
544protein structures are not rigid crystals,112,113 being better
545described in terms of the dynamic conformational ensembles.
546Therefore, the ligand binding may simply result in the
547population shifts of the conformational states in these dynamic
548ensemble.114 These considerations eventually resulted in the
549paradigm shift, and although the allostery concept was
550originally proposed for the description of enzymes, later it
551was extended to all proteins, and a new view of this
552phenomenon was proposed.107 This new view pointed out
553that because allostery is a consequence of redistributions of
554protein conformational ensembles, and because appropriate
555ligands, point mutations, or external conditions may facilitate a
556population shift within these ensembles, all proteins can be
557allosteric.107 The next logical development was incorporation of
558the intrinsic disorder phenomenon to the picture of allosteric
559regulation.108 By considering a simple model of a two-domain
560protein, each domain of which was able to be independently
561folded or unfolded, Hilser and Thompson convincingly showed
562“that site-to-site allosteric coupling is maximized when intrinsic
563disorder is present in the domains or segments containing one
564or both of the coupled binding sites.”108 Furthermore, this
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565 extended consideration of allostery, where intrinsic disorder can
566 maximize the ability to allosterically couple two sites, provides
567 logical explanation and a general quantitative rationale for the
568 high prevalence of disorder in various regulatory proteins, such
569 as transcription factors.115 Also, this consideration opens an
570 absolutely new way to look at the site-to-site coupling, “wherein
571 the abilities to propagate the eﬀects of binding are determined
572 not necessarily by a mechanical pathway linking the two sites,
573 but by the energetic balance within the protein (i.e., what states
574 are most stable and what ligands can bind to each state).”108
575 These theoretical considerations were supported by recent
576 empirical studies, which also granted a strong support to the
577 concept of the disorder-based directional assembly of functional
578 complexes. For example, a multiparametric analysis of the phd/
579 doc antitoxin−toxin operon and related three-component
580 network formed by toxin (Doc), antitoxin (Phd), and their
581 operator DNA revealed the importance of intrinsic disorder for
582 the conditional cooperativity of this system.116 Antitoxin Phd
583 possesses an intrinsically disordered C-terminal domain that
584 folds into an α-helix upon binding to the toxin Doc, and an N-
585 terminal dimerization domain that binds to DNA and represses
586 the transcription of the operon.117,118 Recently, using NMR
587 spectroscopy, this N-terminal domain was shown to behave as a
588 conformationally heterogeneous protein that populates folded
589 and disordered states.116 It was also shown that the Doc-
590 mediated enhancement of Phd binding to operator that
591 represents an illustration of the conditional cooperativity (or
592 directional assembly) can be explained by the intrinsic disorder-
593 based allostery. Here, monomeric Doc engages two Phd dimers
594 on two unrelated binding sites. The binding of Doc to the
595 intrinsically disordered C-terminal domain of Phd resulted in
596 structurization of its N-terminal DNA-binding domain,
597 illustrating allosteric coupling between highly disordered and
598 highly unstable domains.116
599 Finally, smFRET was recently used to provide a detailed
600 description of the allosteric eﬀects involved in the coupled
601 binding and folding processes associated with the formation of
602 the ternary E1A system, consisting of the intrinsically
603 disordered adenovirus early region 1A (E1A) oncoprotein,
604 the general transcriptional coactivator CREB binding protein
605 (CBP), and the retinoblastoma protein (pRb).119 In the
606 infected cells, E1A recruits numerous cellular regulatory
607 proteins via cooperative use of N-terminal region, and two
608 conserved regions, CR1 (residues 42−83) and CR2 (residues
609 121−139). Among these cellular targets of E1A are CBP (or its
610 paralogue p300) and pRb, each of which binds to two
611 noncontiguous and largely nonoverlapping regions of E1A
612 forming binary E1A−pRb and E1A−CBP complexes, and a
613 ternary pRb−E1A−CBP complex.120 The polyvalent binding
614 needed for the formation of these complexes involves
615 interactions between the TAZ2 domain of CBP/p300 and
616 CR1 and N-terminal region of E1A, and interactions between
617 pRb and E1A involve LXCXE motif (residues 122−126) within
618 the E1A CR2 region and a binding site within CR1 (residues
619 42−49). In a ternary complex, the TAZ2 domain does not
620 interact directly with pRb, being engaged in the complex
621 formation via its binding to E1A.120 On the basis of the details
622 of the formation of various complexes in a wide range of CBP
623 and pRb concentrations, it has been concluded that E1A−
624 CBP−pRb interactions might display positive or negative
625 cooperativity, depending on which domains of E1A are
626 available for interaction with CBP/p300 and pRb.119 It has
627 been pointed out that the positive cooperativity in ternary
628complex formation might be related to the enhancement of the
629E1A critical function, the CBP/p300-mediated acetylation of
630pRb to force permanent exit from the cell cycle and promote
631diﬀerentiation of the host cells. On the other hand, negative
632cooperativity (i.e., preference for binary complexes over the
633ternary complex) was suggested to broaden the stimulus range
634via increasing the population of intermediate binding states
635(binary complexes), facilitating their interactions with other
636cellular partners, thereby permitting a context-dependent
637modulation of diﬀerent molecular species that contribute to
638the potency of viral E1A in hijacking and exploiting host
639cellular mechanisms.119 On the basis of these observations, it
640has been concluded that “modulation of allostery using
641intrinsically disordered protein regions that can bind to diverse
642partners may be a mechanism by which a promiscuous
643molecular hub IDP can manage its functional complexity.”119
644Overall, intrinsically disordered regions provide a new ﬂavor
645of dynamic allostery.121 In a classical case, dynamic properties
646of a binding interface can be tuned by a ﬂexible regulatory
647region.122,123 In disorder-based interactions, regulatory sites can
648remain conformationally heterogeneous in the complex; thus
649the protein is represented by a structural ensemble in both
650unbound and bound forms.124 Shifting population of various
651structural states within the ensemble can be induced by
652environmental signals and can be realized via multiple
653pathways.125 This also implies that disordered segments can
654be subjected to further modiﬁcations (e.g., PTMs),126 which
655can modulate the ensemble by reshaping the energy landscape
656of the disordered protein. Thus modiﬁcations or interactions
657with further partners could function as a dynamic relay, which
658aﬀects conformation or ﬂexibility of the binding interface.
2.4. Complex Assembly, Evolution, and Intrinsic Disorder
659A correlation was uncovered between the assembly and
660evolution of protein complexes, where both of the processes
661tend to follow similar pathways. In other words, protein
662complex assembly reﬂects the quaternary structure evolution of
663a given protein complex.106 As pointed out above, speciﬁc
664assembly intermediates are observed in the protein complex
665assembly, where the largest intersubunit interfaces are formed
666ﬁrst, and the smaller interfaces are formed later (and broken
667ﬁrst during disassembly, which is generally reversible).106 In
668agreement with this hypothesis, the analysis of the putative
669evolutionary pathways of a large number of homo-oligomers
670revealed that the evolutionary intermediates tend to have the
671same quaternary structure as the predicted assembly
672intermediates, and thus there is a strong tendency for the
673assembly pathways of homo-oligomers to recapitulate their
674evolutionary histories, with assembly intermediates resembling
675subcomplexes that are conserved in evolution.103,104,127
676Furthermore, predispositions for local ﬂexibility, global
677conformational dynamics, and large-scale conformational
678ﬂuctuations are also related to and reﬂected in evolution.
679Here, local ﬂuctuations and the intrinsic disorder propensities
680correlate with the evolutionary rates, whereas global dynamics
681(where proteins undergo large-scale motions involving multiple
682residues moving together in a collective manner) reﬂect
683evolutionary variance.106 For ordered proteins, the evolutionary
684conservation of the peculiarities of protein dynamics correlates
685with the conservation of structural elements.106 As was
686mentioned above, the directionality of protein complex
687assembly suggests that the most thermodynamically stable
688subcomplexes, which are most likely to be seen in assembly and
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689 which are most likely to be formed ﬁrst, are the assembly
690 intermediates that form the largest interfaces and bury the most
691 surface area. The very similar trend is also observed in the
692 evolution of the protein complex assembly, where the
693 subcomplexes conserved in evolution are subcomplexes that
694 bury the most surface area.128 Again, as it follows from the
695 Gunasekarant et al. analysis of the protein complexes,64 two-
696 state oligomers, that is, multimers that are formed via the
697 coupled binding and folding mechanism by IDPs or proteins
698 with IDPRs, are characterized by the largest interfaces.
699 Therefore, we can speculate that the formation of at least
700 some most stable and evolutionary conserved subcomplexes is
701 an intrinsic disorder-based process.
3. ILLUSTRATIVE EXAMPLES OF PLIABLE
702 PROTEINACEOUS MACHINES
3.1. Mediator Complex and Transcription Regulation in
703 Eukaryotes
704 3.1.1. Malleability of the Mediator Complex. The
705 Mediator complex is a central element of the eukaryotic
706 transcriptional regulation, which conveys signals from gene-
707 speciﬁc transcription factors (TFs) to the general transcription
708 machinery.129−131 The human Mediator is an assembly of 26
709 subunits,132 but the number of subunits varies between species.
710 The Mediator can stimulate basal transcription133 and as an
711 interface between RNA polymerase II (RNAPII) apparatus and
712 hundreds of transcription factors can also function as a
713 coactivator or corepressor.134 Despite intense eﬀorts since its
714 discovery in the early 1990s, a molecular interpretation of how
715 this multisubunit assembly impacts eukaryotic transcription
716 depending on external signals has remained rather elusive.
717 X-ray crystallography and electron microscopy (EM)
718 structural studies in combination with biochemical experiments
719 indicated that functional versatility of Mediator is intertwined
720 with its structural heterogeneity. Here, we aim to detail how
721 dynamic regions contribute to the organization of Mediator’s
722 architecture, and how they inﬂuence conformational changes
723 required for diﬀerent transcriptional outputs. We will also
724 discuss how intrinsically disordered (ID) regions facilitate
725 communication within the complex enabling a collective action
726 of the individual subunits.
727 3.1.2. Modular Architecture of Mediator. The Mediator
728 has a variable subunit composition, which also depends on
729 organism and cell type.135 The Mediator is assembled from four
f4 730 structural modules: Head, Middle, Tail, and Arm (Figure 4). In
731 addition, the dissociable Cdk8 kinase module also signiﬁcantly
732 inﬂuences the regulatory potential of Mediator.
733 The Head is responsible for interactions with Pol II and the
734 basal machinery.136,137 Mutations in the Head were shown to
735 abolish mRNA synthesis in vivo.138,139 The Tail is the primary
736 target of regulatory signals by transcription factors. The Tail
737 recruits Mediator to gene-speciﬁc promoters in yeast.140
738 TATA-containing and SAGA-dependent genes were aﬀected
739 by impairment of Tail’s function.141 The Middle module
740 bridges between the Head and the Tail via ﬂexible joints.142,143
741 It also provides a platform for interactions with the dissociable
742 cyclin-dependent kinase 8 (Cdk8) module, which could repress
743 activated transcription.144 The kinase module provides an
744 additional 4 subunits to the whole Mediator complex. The
745 transcription repression of the kinase module is independent of
746 the kinase activity of Cdk8 and is likely related to blocking the
747 interactions with RNAPII. Apart from the Cdk8 kinase activity,
748other Mediator subunits are largely devoid of enzymatic
749activities.145 The Arm extrudes from the Middle module and
750has been recently deﬁned as an independent unit based on
751mobility analysis.146 The biological role/relevance of the
752diﬀerent subassemblies on their own still remains an open
753question.
754High-resolution structures are only available for the Head
755 f5module (Figure 5),147,148 while the other modules as well as the
756intact complexes were only studied by cryo-electron micros-
757copy (cryo-EM) at a signiﬁcantly lower resolution.132,149
758Biochemical data provided critical points for docking X-ray
759structural data of heterodimer or trimer subcomplexes into the
760EM models.
7613.1.3. Organization and Conformational Heterogene-
762ity of the Head Module. The Head module is composed of
763seven subunits, Med6, Med8, Med11, Med17, Med18, Med20,
764and Med22, which are organized into three structural domains,
765neck, ﬁxed jaw, and movable jaw (Figure 5A). The Head has a
766vital role in interacting with general transcription factors TFIID
767and TFIIH as well as RNAPII.143 Med17 is central to the
768organization of the assembly. On the basis of a 4.3 Å resolution
769X-ray crystallography analysis of the Saccharomyces cerevisiae
770(Sc) complex,147 formation of the Head starts with Med17,
771Med11, Med22 trimer. This is followed by interactions with
772Med6 and Med8, while the Med18−Med20 heterodimer binds
773the C-terminal region of Med8. The importance of Med17 is
774also reﬂected by the loss of transcriptional activity upon
775deletion of Med17 C-terminal domain (CTD).
776A higher resolution analysis of Schizosaccharomyces pombe
777(Sp) Head at 3.4 Å provided a more detailed picture of eight
778distinct structural elements.148 These resemble a crocodile head
779(Figure 5B), also revealing various additional parts: a joint
780between the ﬁxed jaw and the neck, arm, shoulder, ﬁnger, which
781could not be observed previously. Although the Sc and Sp
782sequences exhibit only 15% sequence similarity, the structures
783are well-conserved. The Sp Head structure possesses four
784ﬂexible elements: the shoulder, the ﬁnger, movable jaw, and the
785nose. The loop regions and structurally undeﬁned regions are
786critical to mediate intersubunit contacts in both Sp and Sc
787complexes (see below).
788The Head module was observed to exhibit a number of
789diﬀerent conformations in isolated form.143 These mostly diﬀer
790in orientation of the neck with respect to the jaws and the
791closed/open status of the jaws. The movable jaw in the Head,
792which consists of the Med8/Med18/Med20 heterotrimer, was
793demonstrated to have multiple orientations,147 which resulted
Figure 4. Schematic representation of Mediator subunits: Head
(orange), Middle (green), Tail (yellow), kinase module (blue).
Subunits likely belonging to the Arm are shown by gray. Darker colors
mark subunits, which are enriched in disordered regions.
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794 in diﬀerent overall conformations of the Head module. The
795 position of the shoulder changes due to ﬂexible connections to
796 Med6, which in turn plays a critical role in transducing signals
797 from the Tail to Head and eventually to RNAPII.148
798 Structural studies also indicated a variety of conformations in
799 the context of the intact Mediator.146 Such structural
800 heterogeneity can be utilized for RNAPII interactions via
801 selecting/inducing appropriate conformations for formation of
802 the preinitiation complex (PIC). Indeed, cryo-EM data showed
803 large-scale structural changes of the Head upon interacting with
804 RNAPII.143 A remodeling of the Head subunits involves a close
805 to open transition of the jaws upon assembly of the PIC.
806 3.1.4. Structural Versatility of the Mediator. The ﬁrst
807 EM pictures provided evidence for conformational variability of
808 Mediator.150 Even in the absence of RNAPII binding,
809 conformational ﬂexibility among diﬀerent subunits was
810 demonstrated in yeast.151 Recently determined crystal
811 structures exhibit marked conformational diﬀerences even
812 within the same organism.147,152 The human Mediator complex
813 was also found to be extremely dynamic.153 Binding of RNAPII,
814 activators, or the Cdk8 module triggers substantial structural
815 shifts throughout the complex.145 Despite the low sequence
816 similarity between yeast and human Mediator, the overall
817 structural organization and large-scale changes in its con-
818 formation appear to be well-conserved.146 These were
819 suggested to underlie the extremely versatile and complex
820 transcriptional regulation of Mediator. Below, the possible
821 functional importance of conformational heterogeneity will be
822 discussed.
823 3.1.4.1. Structural Shifts upon RNAPII Binding. The Head
824 interactions with TATA-box binding protein (TBP) were found
825 to increase basal transcription levels.143 This was due to a shift
826 in conformational equilibrium toward an open conformation of
827the movable jaw. In the absence of TBP, the jaw established
828additional interactions with Med17, and the closed form is
829preferred. TBP most likely contacted Med8, although the
830corresponding electron density could not be unequivocally
831determined. This might be due to ambiguity in the
832corresponding interactions, also termed as fuzziness.154 On
833the other hand, the interactions with RNAPII also induced
834changes in the polymerase conformation and facilitated clamp
835opening,155 which increased basal transcriptional activity. The
836Arm module was also observed to undergo extensive
837rearrangement upon interacting with RNAPII.146 General
838transcription factors could further contribute to alterations of
839the human Mediator RNAPII structure, as it was observed for
840TFIIF.153
841The Head induces phosphorylation of RNAP CTD by
842TFIIH.156 EM images showed strong interactions of RNAPII
843CTD with the Middle and indicated a weak binding site on the
844Head.143 The CTD contacts mainly the Med6, Med17, and
845Med8 of the Head in an extended conformation.152 The weak
846interactions are realized in a variety of ways, which might
847account for some diﬀerences between human and yeast
848holoenzymes.146
8493.1.4.2. Structural Changes upon Gene-Speciﬁc TF Bind-
850ing. The Mediator does not exhibit sequence-speciﬁc DNA
851binding activity; thus its promoter selective regulatory functions
852rely on TF binding.140,145 Activation and repression of gene
853expression is mostly controlled by the impact of Mediator−TF
854interactions on RNAPII activity. The structure of human
855Mediator changes upon TF binding, which could be utilized as
856a conformational “marker” to process transcriptional signals.
857TF-induced speciﬁc structural shifts enable Mediator to carry
858out gene-speciﬁc functions by introducing new Mediator−
859cofactor interactions.157 These structural changes were
Figure 5. Crystallographic analysis of Mediator Head module. (A) Crystal structure of the Head subunits from Saccharomyces cerevisiae by Imasaki et
al. at 4.3 Å resolution147 and (B) crystal structure from Schizosaccharomyces pombe by Lariviere et al. at 3.9 Å resolution.148 Med6 (brown), Med17
(red), Med11 (wheat), Med8 (yellow), Med18 (lime), Med20 (blue), Med22 (orange). Gaps in the structure indicate disordered regions. Names of
the diﬀerent domains are indicated as underscored. (C) Topological arrangements of disordered regions in the Head module: fuzzy regions, which
are disordered even in the complex, are yellow; disordered regions, which fold upon interaction, are orange; and ordered protein interaction sites are
blue. The ID binding site in human Med17, where L371P mutation contributes to infantile cerebral atrophy, is shown by red.
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860 proposed to propagate through the entire complex. The
861 composition of Mediator, on the other hand, did not change
862 upon TF interactions, underscoring the functional importance
863 of structural changes. This might also implicate that the
864 diﬀerent TFs interact with diﬀerent subunits, and thus have a
865 diﬀerent modulatory eﬀect on Mediator’s structure.
866 Although EM analysis of both yeast and human Mediator
867 revealed signiﬁcant conformational ﬂexibility,158,159 no long-
868 range correlations were observed between diﬀerent parts of the
869 structure.146 Hence, a speciﬁc (i.e., gene-speciﬁc) binding event
870 does not induce formation of a single conformation, which
871 corresponds to a given functional outcome. Instead, conforma-
872 tional heterogeneity is preserved even upon TF interaction, and
873 the equilibrium is shifted accordingly. Such mechanism can
874 underlie a rapid response to numerous signals.
875 The heterogeneity of Mediator contacts with RNAPII
876 suggests a dynamic exchange at actively transcribed genes.
877 From initiation to elongation, RNAPII must break contacts
878 with the PIC. It appears that activator-induced changes in
879 Mediator structure facilitate promoter escape and the switch to
880 elongating state.153 Activation domain (AD) of p53 was indeed
881 shown to interact with diﬀerent Mediator subunits, each
882 aﬀecting Mediator’s structure diﬀerently with varying impact on
883 RNAPII activity.160 Only the p53 activation domain, but not
884 the p53 CTD, triggered the transition of RNAPII to elongating
885 state. Mediator was shown to be crucial for phosphorylation of
886 RNAPII CTD. In this manner, the RNAPII CTD processing
887 was also related to diﬀerent structural states of the p53 AD−
888 Mediator complex. In the presence of VP16 activator,
889 conformational heterogeneity was observed in low-resolution
890 cryo-EM data of the human Mediator RNAPII complex.132,161
891 Structural changes due to VP16 were similar to those that were
892 induced by RNAPII binding, suggesting that the structural state
893 could control Mediator’s biological activity.
894 All of these mechanisms could correspond to postrecruit-
895 ment of gene-activation, when the stalled/paused polymerase is
896 reactivated in a context speciﬁc manner.
897 3.1.4.3. Structural Changes upon Binding of the Cdk8
898 Kinase Module. The 2D EM map indicated that Mediator
899 interacts with the kinase module in multiple ways.144 Cdk8 and
900 Med13 are located at the opposite ends of the kinase module
901 and mediate interactions with other modules. Med13 interacts
902 with a “hook” that serves as an anchor of the main Mediator
903 structure,162 while Cdk8 at the other end exhibits less frequent
904 contacts with the Middle. The interaction with Med13 is the
905 dominant one, whereas the one with Cdk8 has variable
906 positions, that is, “fuzzy” even in the context of other subunits
907 of the kinase module.144 Overall, the Mediator has an extended
908 shape upon interacting with the Cdk8 kinase module, which
909 provides a large binding interface for the kinase module.
910 Cdk8 module−RNAPII antagonism for Mediator binding
911 represents a key regulatory checkpoint.162 The kinase module
912 in the yeast complex was found to block a binding site required
913 for RNAPII.163 The Cdk8 kinase module in the human
914 complex, however, was proposed to inhibit RNAPII inter-
915 actions via inducing conformational changes in other Mediator
916 modules.162 EM analysis of the diﬀerent constructs excluded
917 the possibility that the kinase module interacts with the Tail
918 directly, so its eﬀect is also likely propagated via conformational
919 changes.
920 3.1.5. Experimentally Detected Disordered Regions in
921 Mediator. Both X-ray crystallography and EM studies
922 corroborate that the overall structural organization of human
923and yeast Mediator is dynamic. Flexibility of various subunits
924was also demonstrated in detail, for example, those of the
925connecting joints between the diﬀerent modules and
926submodules. The importance of structural variability in
927modulating RNAPII activity was discussed above. Some
928regions, however, could not be resolved either in high- or in
929low-resolution electron density maps. These segments lack a
930well-deﬁned tertiary structure, termed also as IDPR.1 IDPRs,
931for example, could serve as a link between globular domains.
932They also facilitate protein−protein interactions and contribute
933to formation of subunit contacts.164
934Med17 serves a central role in organization of the Head
935structure by anchoring other subunits.147 Truncating the N-
936terminal region of yeast Med17, however, did not cause a
937considerable loss in electron density.143 This indicates the
938presence of an IDPR (∼1−200) in accord with the segment
939predicted by bioinformatics methods (Figure 5C). The linker
940region in Med17 (320−420), connecting the helical bundle
941domain and the C-terminal domain, is not fully visible in the
942crystal structure and contains a >20 AA long disordered
943region.152 This contributes to variable position of the jaws with
944respect to the neck and facilitates more eﬃcient interactions
945with RNAPII. The movable jaw is comprised by the Med18−
946Med20−Med8 heterotrimer. Its orientation is controlled by the
947interactions of Med18 loop with the C-terminal region of
948Med17, and N-terminal region of Med11.147 Both are mediated
949by an ID binding region in Med18, and the N-terminal domain
950(NTD) of Med11 is also disordered. The ﬂexibility of the neck
951and jaws stems from a poorly ordered Med18 region (110−
952144) of the central joint.152 This region is ﬂanked by two ID
953binding regions, but itself does not adopt any stable structure
954even in the context of other subunits. Such regions, which are
955disordered in the bound form, are termed fuzzy.31 They could
956contribute to structural multiplicity/heterogeneity in the bound
957form by establishing ambiguous/transient interactions in a
958complex.124 Other regions, which were not present or could not
959be modeled in the crystal structure of the Sc and Sp Head, were
960also predicted to be disordered.165 The functional importance
961of some of them will be discussed below.
962The Med7/Med21 heterodimer is located at the Head−
963Middle interface, and its coiled coil architecture establishes
964interactions with Med6 of the Head and likely contributes to
965signal transduction toward the basal machinery.143 The N- and
966C-terminal regions of Med7 are predicted to be disordered, and
967were shown to fold only when in complex with Med21.166
968Because of their elongated shape, the Med7/Med21 dimer
969serves as a ﬂexible hinge, which could contribute to propagating
970structural changes between the diﬀerent modules of the
971Mediator complex. The interface between the Head and
972Middle modules is indeed important, facilitating a reorganiza-
973tion of Mediator’s structure and inducing a conformation
974compatible with RNAPII binding.
975Med13 is part of the Cdk8 kinase module, which can be only
976poorly localized in EM images. Deletion of Med13, however,
977signiﬁcantly reduces the size of the structure, indicating that
978this subunit is not ordered.144 This is consistent with the
979predicted high degree (>70%) of disorder of Med13,165 which
980is preserved even within the complex. Med13 is a target of post-
981translational modiﬁcations (PTM) and thus imparts PTM-
982dependent transcription regulation on the Mediator com-
983plex.167
9843.1.6. Abundance of Predicted Disordered Regions in
985Mediator. Structural and biochemical data indicate that
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986 conformational heterogeneity and dynamics is essential for the
987 organization of Mediator’s structure and its regulatory
988 mechanisms. Experimental characterization of disordered
989 regions, however, presents a bottleneck in investigations of
990 Mediator’s function. Two independent bioinformatics meth-
991 ods168,169 were applied to identify ID segments in all Mediator’s
992 subunits, where sequences are available. First, the experimen-
993 tally most studied yeast and human Mediator will be discussed.
994 The analysis was also extended to 340 sequences from 27
995 eukaryotic organisms.165
996 Out of 25 subunits that were studied in Saccharomyces
997 cerevisiae and Homo sapiens, 5 and 7 were found to be
998 dominantly disordered, that is, comparable to experimentally
999 veriﬁed disordered proteins in the DisProt database.170 These
1000 subunits likely lack a well-deﬁned tertiary structure and can
1001 simultaneously exist or interconvert between diﬀerent con-
1002 formations. In yeast, dominantly disordered subunits are mostly
1003 localized in Tail (Med2, Med3, and Med15), while in human
1004 they are in the Middle (Med1, Med4, Med9, Med19, and
1005 Med26). In addition, the human Med8 (Head) and Med15
1006 (Tail) and yeast Med9 and Med19 (Middle) were found to be
1007 highly dynamic. This suggests that pliability in yeast is mostly
1008 required for TF interactions and inducing gene-speciﬁc
1009 responses, while in human for propagating conformational
1010 signals either from the Tail or from Cdk8 module to Head and
1011 the basal machinery to impact RNAPII activity. Sequences from
1012 other subunits indicate enrichment in disorder for Med6,
1013 Med17, Med22, Med28, and Med30 (Head); Med7, Med21,
1014 and Med26 (Middle); as well as Med12 and Med13 (Cdk8
1015 module). Along these lines, amino acid compositions of all
1016 modules are dominated by polar, charged, and structure-
1017 breaking residues and depleted in hydrophobic residues relative
1018 to globular proteins. This indicates less tightly packed (less
1019 compact) structures, in accord with malleability of the whole
1020 complex. Conformational pliability of Mediator due to the
1021 presence of disordered regions facilitates rearrangements that
1022 expose a huge surface area to enable extensive contacts with
1023 RNAPII upon interaction.
1024 Almost all modules were found to contain continuous
1025 stretches of disordered residues, which can also play functional
1026 roles. They can serve as linkers between globular structural
1027 domains, can mediate interactions, or can facilitate conforma-
1028 tional changes.164 Indeed, the propensity of long IDPRs
1029 exceeds that of signaling proteins.165 In both human and
1030 yeast Mediator, the Tail was observed to be most enriched in
1031 disordered segments. IDPRs longer than 100 residues can be
1032 found in >60% of proteins in both organisms. The largest ID
1033 segments in yeast are Med2 (334 AA), Med3 (256 AA), and
1034 Med15 (263 AA) of the Tail, and Med1 (645 AA), Med9 (241
1035 AA), and Med26 (261AA) of the Middle in human Mediator.
1036 The enrichment of long ID regions relative to complexes of
1037 similar size indicates that these are required for regulatory
1038 functions in addition to structural organization/assembly of the
1039 complex.
1040 The functional importance of ID regions can also be inferred
1041 from their evolutionary conservation. In case of globular
1042 proteins, amino acid similarity could indicate regions with
1043 conserved roles. Because the high mutation rates in disordered
1044 regions,171 amino acid conservation cannot be conveniently
1045 utilized for identiﬁcation/assessment of functional segments.172
1046 In Mediator subunits, the amino acid similarity is also rather
1047 low (<10% for most subunits), especially in ID segments.173
1048 The presence of repeat regions (polyQ and polyN in Med1,
1049Med9, Med10, Med12, and cdk8) contributes to rapid
1050evolution of Mediator subunits. In contrast to sequence, the
1051similarity of the arrangement of globular and ID regions is high
1052(>60−80%).165 This suggests that, despite the rapid amino acid
1053changes in ID regions, the topology of ordered-disordered
1054segments is highly conserved. Thus, a given coarse-grained
1055structural feature, variation of ﬂexibility/dynamics, is an
1056essential component of Mediator’s function.
10573.1.7. Distinguished Peptide Motifs Mediating Inter-
1058actions in Mediator. Mediator could utilize ID regions for
1059molecular recognition either with other subunits within the
1060complex or with external factors (TFs, or Cdk8 module). Short
1061segments of ID regions, which are distinguished in partner
1062recognition, can exhibit transient secondary structure in the
1063unbound form. These preformed elements174 or MoRFs16 are
1064stabilized by the interacting partner, and the conformational
1065equilibrium is shifted accordingly.
10663.1.7.1. Preformed Elements and α-Helical Recognition
1067Features. Both yeast and human Mediator are enriched in
1068motifs (43 and 79, respectively), which are biased for α-helical
1069conformation.165 The Med18/Med20 heterodimer of the
1070Head175 contacts Med8 via a helical recognition element, also
1071 f6termed as an α-MoRF (Figure 6). This C-terminal region
1072encompassing residues 193−210 of Med8 is ﬂanked by a
1073disordered region, which is not visible in the complex (PDB
1074code: 2hzs). Proteolytic sensitivity of this fuzzy linker is
1075consistent with its disordered state, enabling one to harbor
1076elongin B and C for in vivo transcription.176 The 195−212
1077region of the Med7 in Middle adopts an α-helix upon
1078interacting with Med21 (PDB code: 1yke).166 This C-terminal
1079region could serve to initiate the formation of the coiled-coil
1080heterodimer, which was proposed to serve as a ﬂexible hinge
1081and mediate large-scale changes within the Mediator complex.
1082It also appears to interact with Med10.143
1083Although direct structural evidence is not available for other
1084motifs, their functional relevance could be inferred from in vivo
1085studies. In this manner, the biological roles of 11 α-MoRFs
1086were corroborated in yeast.165 The predicted binding elements
1087in Med3 (333−350)177 and Med15 (116−255) of the Tail are
1088target sites for transcriptional activators (e.g., GCN4, Tup1).
1089Glucocorticoid receptor also has an interaction site on Med15
1090overlapping with the predicted α-MoRF (261−351).178 Med13
1091of the Cdk8 module has three distinct interaction sites for three
Figure 6. Role of disorder in the Mediator formation. α-Helical
molecular recognition element (red) mediates binding of Med8 to
Med18 (dark gray)/Med20 (light gray) heterodimer. It is embedded
in a larger disordered region.
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1092 diﬀerent partners: Caf1, Crc4, and Not2.179 Med17 of the Head
1093 also comprises various disordered interaction motifs.
1094 All of these binding features, out of which many are exposed
1095 in the RNAPII−TFIIF complex, enable contacts and distinct
1096 (i.e., gene-speciﬁc) responses with versatile partners and
1097 thereby contribute to the complex signaling mechanism of
1098 the Mediator. Post-translational modiﬁcation sites could
1099 provide another layer of complexity. PTMs are preferably
1100 located in ID regions, and, for example, T237 in Med4
1101 (Middle) was shown to enhance RNAPII CTD phosphor-
1102 ylation.180
1103 3.1.7.2. Phenotypic Changes Related to Intrinsically
1104 Disordered Binding Sites. Interaction-speciﬁc ID regions do
1105 not always adopt regular secondary structures, even if they fold
1106 in the presence of the partner.181 These regions can be
1107 identiﬁed on the basis of lower degree of disorder with respect
1108 to their environment and their ability to get stabilized by
1109 intermolecular contacts182 (Figure 5). Various known muta-
1110 tions (Saccharomyces cerevisiae) in the Head, which cause
1111 phenotypic changes,148 overlap with such intrinsically disor-
1112 dered binding sites (IDBSs).
1113 For example, temperature-sensitive mutations S226P and
1114 F649S of Med17137 aﬀect intersubunit stability by decreasing
1115 the interaction propensity of the corresponding IDBs. The
1116 F159Y in med17−158183 also contributes to destabilizing the
1117 ﬁxed jaw by protein−protein interactions. The E17K and L24K
1118 replacements in Med11184 also inﬂuence temperature sensi-
1119 tivity and were predicted to mediate protein interactions. In
1120 med6-ts1, med6-ts2, and med6-ts6, six mutations185 aﬀect
1121 intrinsically disordered binding regions, by stabilizing/destabi-
1122 lizing the predicted interaction sites upon contacting the
1123 partner.
1124 Mutations could also interfere with interactions with Rpb3 of
1125 RNAPII. For example, I128V in med17-sup1 rescues the
1126 A159G Rpb3 phenotype183 that is also part of a disordered
1127 protein binding site.
1128 It is important to note that, in addition to IDBs, phenotypic
1129 mutations are also associated with fuzzy regions, which remain
1130 disordered in bound state. For example, in Med6, ∼50% of the
1131 temperature-sensitive mutations are located in fuzzy segments,
1132 illustrating that modulating dynamics strongly interferes with
1133 structural organization and function of Mediator.148,185
11343.1.8. Functional Signiﬁcance of Disordered Regions
1135in Mediator. 3.1.8.1. Mutations in Disordered Regions Can
1136Cause Malignancies. A growing amount of evidence
1137demonstrates the involvement of Mediator in human
1138diseases.186,187 These could be related to mutations, which
1139aﬀect the assembly of the PIC, interfere with RNAPII activities,
1140or perturb the switch to elongation. The L371P mutation in
1141human Med17, for example, is associated with infantile cerebral
1142atrophy.188 This mutation destabilizes a disordered binding site
1143embedded in a longer disordered (fuzzy) segment in the tooth
1144of the Head (Figure 5). The A335V missense mutation in
1145Med25 is located in a disordered proline-rich region, which
1146connects two functional domains. This segment interacts with
1147SH3 domains,189 and the mutation causes Charcot−Marie−
1148Tooth disease, a peripheral neuropathy. As various subunits
1149(e.g., Med12) are involved in signaling pathways, such as
1150Notch, Wnt, or Sonic hedgehog pathways,190,191 mutations
1151aﬀecting the communication/interaction with the signaling
1152proteins can also result in malignancies, for example, in brain
1153development. Similarly to transcriptional activators, pathogenic
1154viruses (e.g., E1A, herpes simplex VP16, Kaposi’s sarcoma
1155associated virus) also target gene-speciﬁc regulatory sites in
1156Mediator and reprogram the host cell transcription machi-
1157nery.192
1158Overall, both experimental and computational evidence
1159corroborates the importance of conformational heterogeneity
1160or actual disorder in Mediator’s function. Disordered regions,
1161which impart pliability on the complex, are structurally, but not
1162sequentially conserved. Functional sites embedded within these
1163regions, for example, binding sites that adopt a stable structure
1164upon interactions, were shown to contribute to the
1165organization of the complex or mediate interactions with
1166transcriptional regulators. The diverse response of Mediator to
1167cellular signals also originates in those regions that retain their
1168conformational freedom in the bound form (i.e., fuzzy), which
1169can induce large-scale structural changes upon diﬀerent
1170transcriptional activators/repressors. Identifying disordered
1171regions and the embedded functional motifs thus could
1172contribute to a better understanding of the Mediator’s
1173mechanism and possibly provide means to interfere with
1174diﬀerent activities.
Figure 7. ATP-dependent proteases share a common architecture. (A) Structure of the proteasome, as modeled from cryo-electron microscopy
(PDB ID 4C0V; ATPγS bound). Two α, two β, and two Rpt subunits were removed to allow visualization of the interior. Only one-half (one α, one
β ring) of the 20S core protease particle and one 19S regulatory particle are shown. (B) Structures of ClpX (PDB ID 3HWS; nucleotide-free) and
ClpP (PDB ID 1Y6G), showing the interior of the barrel. Four out of six subunits of ClpX and four out of seven subunits of ClpP per ring are
shown. (C) Structure of HslUV (PDB ID 1G3I; ATP-bound), showing the interior of the barrel. Four out of six subunits of HslU and V per ring are
shown.
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3.2. Intrinsic Disorder in Protein Unfolding Machines
1175 Organisms synthesize proteins to carry out innumerable cellular
1176 functions, and these proteins must be removed when their
1177 activity is no longer required, they become damaged, or if they
1178 misfold. In all domains of life, eukaryotes, bacteria, and archaea,
1179 this function is primarily carried out by ATP-dependent
1180 proteases,193 and in all cases intrinsically disordered regions
1181 play important roles in the process.
1182 ATP-dependent proteases share a common overall archi-
1183 tecture.193 Proteolysis occurs in the interior of a barrel-shaped
1184 core structure, which is constructed from one or two rings of six
f7 1185 to seven protease subunits per ring (Figure 7). The entrances
1186 to these rings are too small to permit folded proteins inside, so
1187 only unfolded proteins can enter the degradation chamber. A
1188 further, typically hexameric, ring of ATP-dependent motor
1189 proteins stacks on one or both sides of the degradation
1190 chamber, where it unfolds substrate proteins and translocates
1191 them into the degradation chamber for proteolysis. This motor
1192 protein always recognizes a disordered region in the substrate,
1193 but other factors may be needed to bring the substrate to the
1194 protease.
1195 In eukaryotes, cytoplasmic and nuclear ATP-dependent
1196 protein degradation is accomplished by the 26S proteasome
1197 (Figure 7A), a macromolecular assembly of at least 33 proteins
1198 and a total molecular weight of approximately 2.5 MDa. The
1199 proteasome recognizes most of its substrates through poly
1200 ubiquitin tags attached to lysine residues in the substrates.194
1201 Ubiquitin chains are attached through a cascade of three
1202 enzymes, called E1, E2, and E3 enzymes, which activate
1203 ubiquitin (E1) and pass it on to the target proteins (E2 and
1204 E3). Yeast encodes one E2, 11 E2s, and ∼60−100 E3s, and
1205 speciﬁcity is usually conferred by the interaction between the
1206 E3 and the target (reviewed in refs 194,195).
1207 In bacteria, several proteases, including Lon, FtsH, ClpXP,
1208 ClpAP, and HslUV (Figure 7B,C), fulﬁll the function of the
1209 eukaryotic proteasome. They degrade overlapping sets of
1210 protein substrates that they typically recognize through motifs
1211 in their primary sequence.193,196 These sequence elements may
1212 be always exposed for short-lived proteins, or may be exposed
1213 conditionally to enable regulated degradation.193 Many
1214 substrates are recognized directly by the ATPase ring, while
1215 other substrates are shuttled to the protease by adaptor proteins
1216 that bind to both the protease and the target protein
1217 simultaneously.193 In actinobacteria, which contain a protea-
1218 some acquired through horizontal gene transfer, degradation of
1219 some substrates requires the covalent attachment of an
1220 ubiquitin-like protein (although the modiﬁer is not homologous
1221 to ubiquitin).197
1222 Archaea also have a proteasome, albeit one that mostly
1223 selects its substrate in the same way as do bacterial ATP-
1224 dependent proteases. The archaeal proteasome typically
1225 recognizes short sequence tags, but in some organisms is
1226 capable of using small ubiquitin-like modiﬁer proteins (SAMPs)
1227 as targeting signals.193,198 Nevertheless, experimental inves-
1228 tigations into its mechanism have provided many insights into
1229 how the eukaryotic proteasome functions.
1230 In this section, we will discuss the multiple roles that intrinsic
1231 disorder plays in the function of ATP-dependent proteases.
1232 3.2.1. Intrinsic Disorder in the Proteolytic Machine.
1233 The eukaryotic 26S proteasome is composed of two main
1234 assemblies, the 20S core proteolytic particle, and the 19S
1235 regulatory particle (Figure 7A). The 20S particle consists of
1236 four stacked rings, each containing seven α or ß subunits, with
1237the α rings forming the top and bottom layers of the stack and
1238the ß rings, which contain the protease active sites, forming the
1239two middle layers.199 As described below, the isolated 20S
1240particle is largely proteolytically inactive, even with small
1241peptide substrates, because a built-in gate prevents substrates
1242from entering.200 The 19S particle contains the hexameric ring
1243of ATPases (Rpt1−6 in yeast) typical of all ATP-dependent
1244proteases, which binds directly to the α ring, opens the gate,
1245and is responsible for ATP-dependent unfolding and trans-
1246location. The 19S particle also contains some 13 non-ATPase
1247subunits (Rpn subunits 1−3, 5−13 and Sem1 in yeast).194,199
1248These additional subunits recognize, edit, and eventually
1249remove the ubiquitin chains on substrates. They also stabilize
1250both the 19S cap and the entire proteasome particle and serve
1251as an interaction platform for a range of additional proteins
1252such as substrate adaptors and ubiquitin chain modulators.201
12533.2.1.1. Sem1. The proteasomal subunit Sem1 in yeast and
1254its orthologue DSS1 in mammals are components of the 19S
1255regulatory subunit of the proteasome.202 Sem1 and DSS1 are
1256small (89 and 70 residues, respectively), highly acidic, and share
1257a central sequence that is ∼50% identical between yeast and
1258human. Sem1 family proteins are natively disordered in the
1259absence of binding partners, and are the only stoichiometric
1260proteasome subunits listed in DisProt (DP00617). These
1261proteins form well-deﬁned structures when they bind to other
1262proteins, for example, BRCA2 and TREX-2, but the structure is
1263determined by the binding partner and is diﬀerent in each
1264complex.203,204 Recently, the position of Sem1 in the yeast 26S
1265proteasome structure was determined by cryoEM of
1266proteasomes puriﬁed from ΔSem1 and wild-type yeast.205
1267Intriguingly, in the proteasome, Sem1 takes on a diﬀerent
1268conformation than those in BRCA2 or TREX-2 complexes. In
1269the proteasome, it serves to stabilize the interaction between
1270two other 19S subunits, Rpn3 and Rpn7. Deletion of Sem1
1271destabilizes the proteasome structure and attenuates its
1272function in yeast.202,206 Indeed, Sem1/DSS1 has been termed
1273“molecular glue” because of its ability to stabilize a number of
1274macromolecular complexes.207 Presumably Sem1/DSS1’s lack
1275of a native fold gives it the versatility required to perform these
1276functions.1
12773.2.1.2. Gating of the Core Particle. Protease core particles
1278without their caps have little proteolytic activity on small
1279peptides or unfolded proteins, even though such substrates
1280should not require active unfolding. For the proteasome, this
1281lack of activity is due to a gate that is composed of the N-
1282termini of the 20S α-subunits, which sterically block the
1283entrance to the degradation chamber.200 The tails that make up
1284the gate were structured in the closed-gate yeast core particle,
1285but were not observed in the crystal structure of either an
1286archaeal core particle or in a gate-opened mutant missing one
1287of the N-termini.200 Thus, it was originally thought that an
1288order to disorder transition was responsible for gate opening.
1289However, more recent NMR experiments indicate that instead
1290the gate N-termini, although highly dynamic, interconvert
1291between conformations that either occlude the pore or leave it
1292unobstructed rather than becoming disordered.208 The gate
1293opens upon binding of the 19S particle. Tails at the C-terminus
1294of the 19S ATPases Rpt2, Rpt3, and Rpt5 terminate in an
1295HbYX (hydrophobic-tyrosine-any amino acid) motif. These
1296tails dock into pockets between subunits of the 20S α-ring,
1297leading to the reorientation of the α-N-termini and the opening
1298of the gate.209−212 Peptides corresponding to the tails are able
1299to activate the 20S proteasome in vitro, and the crystal
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1300 structures of the C-terminal domain of Rpt3 and the
1301 homologous PAN ATPase that binds to the archaeal
1302 proteasome show no density for the HbYX-containing tails,
1303 suggesting that the tails take on structure only when bound in
1304 their pockets, and therefore that a disorder to order transition is
1305 responsible for docking of the 19S particle and opening the
1306 gate.209,213,214 ClpA and ClpX also activate ClpP toward
1307 peptide hydrolysis upon binding by opening an internal gate,
1308 but here the activation is mediated by ﬂexible loops rather than
1309 C-terminal regions of the unfoldase.215−217
1310 3.2.1.3. Adaptor Proteins. ATP-dependent proteases recog-
1311 nize many of their substrates directly at sequence motifs or
1312 ubiquitin/ubiquitin-like modiﬁcations, as described above.
1313 Other substrates are targeted to proteases through adaptors
1314 or shuttle proteins that can bind both to substrates and to the
1315 protease. Intrinsic disorder plays a role in the ability of some of
1316 these adaptor proteins to deliver a wide variety of substrates for
1317 degradation.
1318 The SspB adaptor targets various substrates to ClpXP for
1319 degradation in bacteria. The dimeric adaptor contains a
1320 substrate binding domain and two ﬂexible tethers that allow
1321 it to dock at the surface of ClpXP, where it hands oﬀ a bound
f8 1322 substrate to the ClpX ATPase (Figure 8A).218 Changes in
1323 tether length change the aﬃnity with which SspB interacts with
1324 ClpXP and thereby change its ability to deliver substrates for
1325 degradation.219 Presumably, some degree of disorder in the
1326 tether is required to allow diﬀerent substrates to bind to the
1327 adaptor and be presented to the motor proteins in the correct
1328 orientation to be grabbed onto and unfolded.
1329 Yeast Rad23, Dsk2, and Ddi1 (and related family members in
1330 mammals) play a similar role in eukaryotes. Rad23 contains an
1331 N-terminal ubiquitin-like (UbL) domain, two ubiquitin-
1332 associated (UBA) domains, and a Rad4-binding domain, all
1333 separated by intrinsically disordered linkers.220 Rad23 serves as
1334 a substrate adaptor for the proteasome by binding to
1335 ubiquitinated proteins through the UBA domains and the
1336 proteasome through the UbL domain and thus bringing them
1337 to the proteasome for degradation (Figure 8B). The disordered
1338linkers may allow Rad23 to present proteins of diﬀerent
1339structures and ubiquitination patterns to the proteasome such
1340that the ATPase motors can engage these substrates.221 The
1341extent to which the bulk of cellular substrates are directly
1342targeted to the proteasome or delivered by adaptors like Rad23
1343remains a topic for further investigation.
13443.2.2. Intrinsic Disorder in Substrates. ATP-dependent
1345proteases are able to unfold their target proteins, but this
1346unfolding activity must be primed with a stretch of the substrate
1347that is already disordered, resulting in multiple possibilities for
1348selectivity and regulation. Other sequences that are predicted to
1349be disordered can actually regulate protease function mid-
1350degradation, preventing unfolding from occurring. Finally, there
1351are many proteins that are intrinsically disordered, and we
1352discuss how this native disorder may make them particularly
1353susceptible to proteasomal degradation.
13543.2.2.1. Initiation of Unfolding and Degradation. Before a
1355folded substrate can be unfolded and degraded by an ATP-
1356dependent protease, it ﬁrst needs to bind to the protease. For
1357the proteasome, this is largely accomplished by a ubiquitin tag
1358attached to the substrate, which is recognized by ubiquitin
1359receptors in the 19S cap.199 However, binding alone is
1360insuﬃcient for degradation to occur. The substrate must
1361contain a disordered region at which the proteasome can
1362engage the protein so that ATPase motors can pull it into the
1363degradation chamber in the middle of the protease particle. The
1364entrance to the chamber is too narrow for folded domains to
1365pass through, and so the domains experience a force that will
1366cause them to unravel.222−224 If continued translocation is then
1367faster than refolding, the protein will be trapped in an unfolded
1368state, translocated into the degradation chamber, and
1369proteolyzed into small peptides. The link between a disordered
1370region and degradation was discovered for the proteasome
1371through the observation that a ubiquitinated protein would
1372remain stable, unless a disordered region was also present.225
1373Degradation would then begin at the disordered region226 and
1374proceed along the polypeptide chain sequentially.227 The
1375disordered region must be long enough to stretch from
Figure 8. Adaptor proteins mediate degradation of some substrates. (A) The adaptor protein SspB (green) binds to ClpX (brown) through long
ﬂexible tails and to a substrate (blue) through the ssrA degradation tag (red), allowing it to present the substrate to ClpX. (B) The adaptor protein
Rad23 contains a UbL domain (purple) that binds to receptors on the proteasome such as Rpn13, as well as two UBA domains (green) that can bind
to ubiquitinated substrates (blue) and present them to the proteasome for degradation. The ﬂexible linkers connecting Rad23 domains may help
position substrates of diﬀerent geometry such that their unstructured initiation regions (red) can engage with the proteasomal motors.
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1376 where the substrate is anchored to the proteasome to their
f9 1377 receptor, which most likely is the ATPase motor itself (Figure
f9 1378 9).221,225 After an initial, ATP-independent ubiquitin-mediated
1379 binding event, the substrate becomes bound more tightly in an
1380 ATP-dependent step that requires an unfolded initiation site or
1381 a weakly folded domain, but no longer requires the ubiquitin.228
1382 These initiation regions can be on the N- or C-terminus of the
1383 protein to be degraded, or can function internally, if they are
f10 1384 suﬃciently long to enter the proteasome as a loop (Figure
f10 1385 10).225,229−232
1386 Bacterial ATP-dependent proteases can bind substrates
1387 directly at sequence motifs in the substrate’s amino acid
1388 chain, and in this case the binding and engagement steps are
1389 diﬃcult to separate structurally and may well be two facets of
1390 the same biochemical event.193 The ﬁrst indication of the
1391 importance of an intrinsically disordered region of the substrate
1392 for unfolding and degradation came from studies of the
1393 degradation of UmuD′ by ClpXP. UmuD′ degradation depends
1394 on short disordered regions in the protein that were not
1395 directly responsible for UmuD′ binding to ClpXP.233,234
1396 3.2.2.2. Disordered Initiation Regions and Selectivity. The
1397 proteasome can even pick a protein containing an initiation site,
1398 but no ubiquitin modiﬁcation, out of a complex containing
1399 another ubiquitinated protein that lacks an initiation site, such
1400 that one protein targets the complex to the proteasome, while
1401 the other protein is selectively degraded (Figure 10).226 The
1402 ability of the proteasome to remodel complexes by extracting
1403 subunits was ﬁrst shown in vitro with model proteins235 and in
1404 yeast with the α2 repressor;236 however, in these cases the
1405 subunit that contains the ubiquitin tag is degraded, presumably
1406 because it also contains the best initiation site for the
1407proteasome. Degradation of only speciﬁc subunits is a key
1408principle in cell cycle regulation, where the proteasome is able
1409to extract ﬁrst the cyclin-dependent kinase (CDK) inhibitor
1410Sic1 from a complex containing a cyclin and CDK to generate
1411an active CDK237 and then later to selectively remove and
1412degrade the cyclin from its complex with CDK.238 In these
1413examples, the substrate protein is engaged by the proteasome
1414and its binding partner escapes. CDK does not contain any
1415disordered regions and cyclin is ubiquitinated at its disordered
1416tail, so because cyclin contains both elements of the proteasome
Figure 9. Initiation of degradation by the proteasome requires a disordered region. A substrate molecule (dihydrofolate reductase, PDB ID 1DRE;
yellow and red cartoon on the left) with a polyubiquitin chain attached (in this case, linear tetra-ubiquitin, from PDB ID 2W9N, purple and cyan
cartoon on the left) and a disordered region (red tail) can be degraded by the proteasome. First the polyubiquitin modiﬁcation docks at the
proteasome (PDB ID 4C0V), presumably to ubiquitin receptors Rpn10 (red) and Rpn13 (purple), either simultaneously (as shown) or individually.
Next, the tail is engaged by the Rpt ATPase motors (orange) in an ATP-dependent process, allowing unfolding, translocation, and degradation
(along with deubiquitination of the substrate) to begin.
Figure 10. Geometries of disordered initiation sites. A protein (blue)
tagged with ubiquitin (purple) and containing a disordered initiation
site (red) of suﬃcient length can be degraded by the proteasome.
Initiation regions can be N-terminal (A), C-terminal (B), internal (C),
or even on a nonubiquitinated protein in complex with a ubiquitinated
protein (D; only blue protein is degraded). The site of ubiquitin
modiﬁcation may be on or near the disordered region.
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1417 degradation signal it is the substrate that is degraded. When all
1418 three proteins are present, only Sic1 is degraded, which is more
1419 puzzling given that both Sic1 and cyclin contain disordered
1420 regions. All else being equal, the proteasome prefers an
1421 initiation region close to the site of ubiquitination to a more
1422 distal disordered region.221 In the homologous mammalian
1423 cyclin A/CDK2/p27Kip structure, the disordered cyclin tail is on
1424 the opposite side of the complex from the site of p27Kip
1425 ubiquitination,239 presumably preventing its engagement by
1426 the proteasome.
1427 The adaptor protein Rad23 described above may rely on
1428 similar principles. It binds to the proteasome through its UbL
1429 domain, but only its binding partner is degraded. Rad23 escapes
1430 because it contains only internal disordered regions, and these
1431 are too short to support initiation.230 Thus, the selection of an
1432 initiation region contributes to the proteasome’s ability to
1433 discriminate between multiple potential substrates. Many other
1434 proteins involved in the ubiquitin−proteasome system, such as
1435 E2 and E3 enzymes, become ubiquitinated and must also have
1436 mechanisms that prevent their degradation by the proteasome.
1437 3.2.2.3. Eﬀects of Disordered Initiation Region Location
1438 on Outcome of Degradation. The location of the disordered
1439 region that serves as an unfolding initiation site also has
1440 important consequences for the ability of a protease to unfold
1441 and degrade its substrates. ATP-dependent proteases can
1442 degrade their substrates from the N- to the C-terminus or
1443 vice versa, but start at the initiation site and proceed linearly
1444 through the rest of the substrate.227 Depending on how diﬃcult
1445 it is to unfold the ﬁrst local structure encountered, degradation
1446 may occur successfully, or the protease may release a partially
1447 degraded substrate, so initiation from the N- and C-terminus
1448 may lead to diﬀerent outcomes.227,240 Degradation can also
1449 begin from an internal disordered loop, and this internal
1450 initiation leads to a lower overall processivity of the
1451 proteasome.231,232 Moreover, the reduction in processivity
1452 seems to depend on the stability of the domains ﬂanking the
1453 internal initiation loop; a more stable domain both resists
1454 degradation itself and protects the domain on the other side of
1455 the loop from degradation,231 presumably because it extends
1456 the time that the substrates compete with each other for the
1457 motor sites. This type of position eﬀect may be part of the
1458 signal that leads to the partial degradation of the transcription
1459 factor Gli3175 to Gli75 upon changes in hedgehog signaling,
1460 because moving the ubiquitination site that drives partial
1461 degradation of Gli3 from the middle of the protein to its
1462 terminus abolishes fragment formation and leads to complete
1463 degradation instead.241
1464 3.2.2.4. Targeting to Bacterial Proteases through Dis-
1465 ordered Regions. The best-characterized targeting sequences
1466 to bacterial proteases like ClpXP are present as N-terminal or
1467 C-terminal extensions, and presumably serve as both binding
1468 tags and initiation regions within a single short disordered
1469 peptide.196,242 Intriguingly, there are a few species of actino-
1470 bacteria that contain both an analogue to the 26S proteasome
1471 (a 20S proteasome plus a ring of ATPases called Mpa) and an
1472 analogue to ubiquitin (PUP, or prokaryotic ubiquitin-like
1473 protein).197 Like ubiquitin, PUP is covalently attached to
1474 substrates targeted for degradation, but the sequences of the
1475 two proteins are not related to each other. PUP is intrinsically
1476 disordered, and its C-terminal region interacts with coiled-coils
1477 present in the Mpa ring, where it becomes structured, forming
1478 an additional coiled-coil helix.243 PUP’s N-terminus remains
1479 disordered, and is engaged by loops within the pore of the Mpa
1480ATPases, which then translocate and unfold the tag along with
1481the attached substrate so they can be degraded.244
14823.2.2.5. Disordered Initiation Regions as Regulatory
1483Elements. The requirement for a disordered region to serve
1484as an initiation site leads to an intriguing possibility for
1485regulation. A region of a protein that can access a structured
1486state when bound to another protein or small molecule, but is
1487disordered in the absence of the binding partner, can become a
1488conditional initiation region. At one extreme, this occurs in the
1489proteasomal degradation of proteins unable to correctly fold.
1490These proteins are recognized by chaperones and at some point
1491ubiquitinated and handed-oﬀ to the proteasome. If correctly
1492folded, most metabolic enzymes and other globular single-
1493domain proteins would, if ubiquitinated, presumably be
1494degraded only slowly, if at all, due to lack of an initiation
1495region (although some proteins are directly destabilized by the
1496ubiquitin tag).245 The misfolded or partially folded form, on the
1497other hand, has regions that are disordered and can therefore
1498serve as initiation sites. This principle is the basis behind several
1499conditional degradation systems in which a mutant of FKBP12
1500is attached to a protein of interest. In the presence of a
1501stabilizing compound, the FKBP domain remains folded, but in
1502the absence of the compound, it unfolds, becomes ubiquiti-
1503nated, and presumably serves as an initiation site for the
1504degradation of the entire fusion protein.246 Kinases that are
1505unstable in the absence of an Hsp90 chaperone cofactor are
1506rapidly degraded by the proteasome when Hsp90 is removed or
1507inhibited, presumably in an analogous fashion.247 Calmodulin,
1508which does not require ubiquitination for degradation, is stable
1509in the presence of Ca2+ but is degraded by the proteasome
1510when Ca2+ is removed or upon aging-induced damage.248 In
1511either case, a ﬂexible or disordered conformation is required to
1512enable degradation. Degradation in bacteria might also be
1513regulated by controlling order−disorder transitions. For
1514example, in the degradation of the Bacteriophage Mu repressor
1515protein, a C-terminal degron must transition from a rigid
1516conformation to an exposed and ﬂexible conformation for
1517ClpXP degradation to occur.249
1518Despite the importance of a disordered or poorly ordered
1519initiation region, there are some proteins that are ubiquitinated,
1520contain a disordered region, but are not degraded by the
1521proteasome. Understanding the properties of disordered
1522regions that are suﬃcient to support degradation will greatly
1523advance our understanding of proteasome’s mechanism.
15243.2.2.6. Disordered Regions That Lead to Incomplete
1525Degradation. Although most proteins that are targeted to the
1526proteasome via ubiquitination are unfolded and completely
1527degraded to small peptides, there are a handful of proteins in
1528which the proteasome removes and degrades one portion of the
1529substrate while releasing another part.250 This released
1530fragment can go on to have a new biological activity. For
1531example, the p105 precursor to the NFκB subunit p50 is
1532processed into the mature form, capable of migration to the
1533nucleus and activation of transcription, by the proteasome.251
1534Other proteins known to be processed by the proteasome are
1535the homologous NFκB subunit p100, which is converted to
1536p52, the distantly related yeast proteins Spt23 and Mga2, the
1537unrelated Drosophila transcription factor Cubitus interruptus
1538(Ci) and its mammalian homologue Gli3, the Epstein−Barr
1539virus protein EBNA1, and just discovered example yeast
1540Def1.241,250,252−254 Although the mechanisms by which
1541complete degradation of the precursor proteins are prevented
1542are still not fully understood, much progress has been made.
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1543 Both p105 and Ci contain a natively disordered region
1544 immediately prior (in the direction of degradation) to the
1545 domain where unfolding and degradation stalls. While in
1546 general it would be expected that an intrinsically disordered
1547 sequence stretch would pose no problem for the proteasomal
1548 degradation machinery, these sequence stretches also possess
1549 unusual amino acid compositions; they are what are termed
1550 compositionally biased regions, in which one or a few amino
1551 acids are over-represented. Such low complexity regions are
1552 associated with the absence of stable structure.255 For p105, Ci,
1553 and model substrates, the presence of a low complexity region
1554 (but not the speciﬁc sequence identity of the low complexity
1555 region) is required for the successful release of a folded
f11 1556 degradation product (Figure 11A).256
1557 Similar sequences exist in other proteins spared in part or in
1558 whole by the proteasome. The Epstein−Barr protein EBNA1
1559 has an extensive set of Gly-Ala repeats that inhibit
1560 degradation.257 In protein folding diseases such as Huntington’s
1561 disease, ubiquitinated proteins containing poly-Gln repeats
1562 resist degradation by the proteasome. Some evidence in cell
1563 culture and mouse models suggests that huntingtin protein
1564 clogs the proteasome, inhibiting the overall functioning of the
1565 ubiquitin-proteasome system,258−260 although other studies fail
1566 to ﬁnd these global eﬀects.261−263 Alternatively, their sequence
1567 composition combined with the stability of aggregates may
1568 prevent their complete degradation.264
1569 In principle, low complexity regions could slip out of the
1570 proteasome more easily, leading to faster substrate dissociation,
1571 they could serve as poor force transducers, making it more
1572 diﬃcult for a substrate domain to be unfolded, or, ﬁnally, they
1573 could get stuck in the proteasome degradation channel or the
1574 sequence composition could slow proteolysis, which could then
1575clog the proteasome, inhibiting degradation. In vitro, the
1576glycine-rich region from p105 stabilizes an adjacent domain by
1577slowing its unfolding rate,264 perhaps because the translocation
1578motor binds these sequences poorly, causing the proteasome to
1579lose its game of molecular tug-of-war with the substrate. This
1580inability to apply force to the substrate still allows the
1581proteasome to hold on to the sequence as long as no force is
1582being applied, thereby leaving the substrate release rate
1583unaﬀected (Figure 11B,C).264 Presumably other low complexity
1584regions act in a similar manner, which would explain the
1585requirement for a neighboring unfolded domain. Bacterial
1586proteases can also be halted by low complexity regions such as
1587glycine-rich regions or Gly-Ala repeats adjacent to a folded
1588domain,240,265,266 and the kinetic mechanism appears to be
1589similar.267 The molecular interaction (or lack of interaction)
1590that leads to this loss of processivity remains to be determined.
1591Sequence complexity is likely one of several factors that
1592determine whether a given protein, upon targeting to the
1593proteasome, is degraded fully or partially, including the location
1594of the proteasome’s initiation region and the stability of the
1595targeted domain against force-based unfolding. For example,
1596Gli3 is processed by the proteasome into a fragment, while the
1597highly similar protein Gli1 is not processed.252 Diﬀerences in
1598both the composition of the low complexity region adjacent to
1599tightly folded zinc ﬁnger domains and the position of the
1600degron targeting the protein to the proteasome, and therefore
1601the likely site of initiation, are responsible for the diﬀerences in
1602processing.241 As described above, the site of initiation can
1603inﬂuence the outcome of degradation both by changing the
1604direction in which the proteasome is moving (and thus the
1605order and direction from which domains are unfolded) and by
Figure 11. Role of low complexity sequences in promoting the release of a fragment from the proteasome. (A) A protein targeted to the proteasome
from the C-terminus will have the C-terminal portion of the protein degraded (green domain), but the presence of a low complexity region and an
additional tightly folded domain (blue domain) leads to the release of a fragment consisting of the domain and a tail composed of part or all of the
low complexity region. Only the endpoint of degradation is shown. (B) With a normal, high complexity sequence adjacent to the blue domain, a
degradation intermediate will form composed of the blue domain bound to the proteasome. This intermediate will then partition between release
and degradation, with degradation typically being faster (thicker arrow) leading to overall degradation of the fragment. (C) With a low complexity
sequence adjacent to the blue domain, unfolding and degradation is slowed with little or no eﬀect on release, leading to an overall reduction in
degradation and accumulation of stable fragment, the same endpoint as shown in plot (A).
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1606 the reduction in processivity that can occur upon initiation
1607 from an internal site within the substrate protein.
1608 In another example, it was recently shown that yeast protein
1609 Def1 is processed by the proteasome into a form capable of
1610 moving to the nucleus, where it helps promote the
1611 polyubiquitination of a component of RNA polymerase II in
1612 response to transcriptional stress.254 Def1 contains an extensive
1613 glutamine-rich region, and processing occurs in a proteasome
1614 and ubiquitin-dependent manner within this region, far from
1615 any known folded domain. On the other hand, there are
1616 predicted coiled-coil sequences within Def1, including two that
1617 would give fragments of the approximate size observed
1618 (between 400 and 500 amino acids) if they blocked
1619 degradation, and it is possible that coiled-coil formation leads
1620 to a stable enough structure that, in combination with a low
1621 complexity region, degradation is inhibited. It is also possible
1622 that the requirements for processing are less stringent in yeast,
1623 which has a less processive proteasome than that found in
1624 metazoans.264 To better understand the mechanism underlying
1625 partial degradation by the proteasome, we require better
1626 understanding of both the sequences that trigger processing
1627 and which protein structures are stable enough to resist
1628 unfolding when combined with such a sequence.
1629 3.2.2.7. Degradation of Natively Unfolded Proteins by the
1630 Proteasome. The main diﬀerence between the targeting of
1631 proteins to the proteasome and to bacterial ATP-dependent
1632 proteases is that most proteasome substrates require both a
1633 ubiquitin modiﬁcation and a separate disordered region, while
1634 most bacterial substrates require a single disordered region that
1635 serves as both the binding tag and the initiation region.268 It
1636 stands to reason, then, that if an initiation region has high
1637 enough aﬃnity for the proteasome, a protein might be targeted
1638 for degradation even in the absence of ubiquitin modiﬁcation.
1639 Indeed, a growing number of proteins have now been discussed
1640 in terms of ubiquitin-independent degradation,269,270 and many
1641 of them are largely or wholly disordered. This lack of structure
1642 in part or all of the protein is essential for degradation, as
1643removing the disordered region from otherwise structured
1644proteins like thymidylate synthase or ornithine decarboxylase
1645protects the protein from degradation.
270 Other largely
1646disordered proteins that can be degraded by the proteasome
1647without ubiquitination include the cyclin-dependent kinase
1648inhibitor p21, the tumor suppressor p53, and the Parkinson’s
1649associated protein α-synuclein.
269 These are likely only a small
1650subset of the proteins that can be degraded without
1651ubiquitination, as it has become increasingly clear that many
1652proteins in the cell are intrinsically disordered, only loosely
1653folded under some conditions, or contain extensive regions
1654with these characteristics.15
1655Completely unfolded proteins such as casein can be degraded
1656by either the 20S or the 26S proteasome without the addition
1657of ubiquitination or another targeting signal.
271 In the case of
1658the 20S proteasome (which lacks the ATPase subunits),
1659degradation is ATP-independent, and unfolded proteins (but
1660not small peptides) are capable of opening the gate that
1661normally prevents substrates from entering.
229 It has been
1662shown that the 20S proteasome can cleave more than 20% of all
1663cellular proteins, and that the 26S proteasome can cleave many
1664of the same proteins in the presence of ATP.
272 Intrinsically
1665disordered regions mediated much of this proteolysis, and the
1666fate of most of these proteins was simple cleavage, not
1667processive degradation. Indeed, susceptibility to cleavage by the
166820S proteasome has been suggested as an empirical way to
1669deﬁne intrinsically disordered sequences,
273,274 and many
1670proteins may be cleaved if not engaged in complex formation
1671or some other interaction that shields them from the
1672proteasome. As this “degradation by default” pathway does
1673not seem to require the proteasome’s unfoldase machinery, we
1674will not address it further here. Those interested are referred to
1675recent reviews, for example, refs 275−277.
Figure 12. Mechanism of nucleocytoplasmic transport through NPCs. Importins (Kapβ1) identify and shuttle NLS-cargo from the cytoplasm into
the nucleus. The Kapβ1−cargo complex is disassembled in the nucleus by RanGTP, and is thought to return to the cytosol with Kapβ1. NES-cargo
requires both RanGTP and exportin for export through NPCs. RanGAP triggers the hydrolysis of RanGTP to RanGDP in the cytosol, which releases
Kaps and cargoes. RanGDP is imported into the nucleus by NTF2, where it is recharged into RanGTP by RanGEF. In the absence of Kaps, neither
speciﬁc nor large nonspeciﬁc cargoes can access the NPC.
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3.3. FG Nups: Intrinsically Disordered Proteins within the
1676 Nuclear Pore Complex
1677 Nucleocytoplasmic transport (NCT) processes are unprece-
1678 dentedly selective, eﬃcient, and robust within the complex
1679 biological milieu.278−280 In eukaryotic cells, biochemically
1680 speciﬁc cargoes comprising of proteins and mRNA are
1681 continuously being exchanged across the nuclear envelope
1682 (NE) that separates the nucleus and the cytoplasm.281 This
1683 occurs through numerous perforations in the NE called nuclear
1684 pore complexes (NPCs),282−284 which are the sole conduits
1685 that bridge the genome to the protein-synthesizing appara-
1686 tus.285 Each NPC is a massive macromolecular complex that
1687 amounts to an overall ∼60 MDa286 and ∼120 MDa287 in yeast
1688 and vertebrates, respectively. With the characteristic species-
1689 dependent diameter of between 50 and 100 nm,288−290 the
1690 NPCs constitute the largest known pores in eukaryotic cells.
1691 Each NPC is constructed from approximately 30 distinct
1692 proteins known as nucleoporins (Nups) that are present in
1693 multiples of eight291 based on the 8-fold symmetry of the
1694 NPC.283,289,290 They are hierarchically categorized into three
1695 architectural subgroups:292 (i) membrane-spanning Nups that
1696 anchor the NPC to the NE; (ii) structural scaﬀold Nups; and
1697 (iii) intrinsically disordered Phe-Gly (FG)-rich Nups (i.e., FG
1698 Nups). The rest of this section is dedicated to discussing the
1699 role of the FG Nups with respect to the regulation of NCT.
1700 3.3.1. NPC Transport Selectivity Depends on FG Nups.
1701 The NPC is a fascinating proteinaceous machine that functions
1702 to restrict or promote bidirectional cargo translocation via
1703 biochemical selectivity and not size exclusion per se. Although
1704 the NPC is permeable to small molecules below ∼40 kDa (e.g.,
1705 water and ions), macromolecules larger than ∼5 nm in size are
f12 1706 generally withheld.293 As shown in Figure 12, rapid and
1707 exclusive access through the NPC is permissible only to soluble
1708 transport receptors294 (i.e., karyopherins or Kaps, but, more
1709 speciﬁcally, importins and exportins) such as the classical 97
1710 kDa import receptor karyopherinβ1 (Kapβ1 or importin β295),
1711 despite exceeding the passive limit. On this basis, NCT is
1712 orchestrated by Kaps that identify, bind, and shuttle signal-
1713 speciﬁc cargoes (via amino acid sequences known as nuclear
1714 localization/export signals (i.e., NLS/NES)) from the complex
1715 biological milieu (sometimes using Kapα/importin-α as an
1716 adaptor) through NPCs.296 Although the translocation of both
1717 importins and exportins is bidirectional, cargo directionality is
1718 regulated by the GTPase Ran, which has GTP- and GDP-
1719 bound forms localized to the nucleus and cytoplasm,
1720 respectively.297 In the nucleus, RanGTP binding triggers the
1721 release of import cargoes from importins, whereas in the
1722 cytoplasm RanGAP (Ran GTPase-activating protein) triggers
1723 the hydrolysis of RanGTP to RanGDP, which dissociates from
1724 its respective karyopherin receptor while releasing export
1725 cargoes from exportins in the process.298 After this, RanGDP
1726 is recycled to the nucleus by its speciﬁc carrier, NTF2 (i.e.,
1727 nuclear transport factor 2).299 In the absence of Kaps, even
1728 signal-speciﬁc cargoes that are smaller entities than entire Kap−
1729 cargo complexes are rejected, which demonstrates the exquisite
1730 selectivity of the NPC.300 In this manner, a cargo is unlikely to
1731 return through the NPC once it has dissociated from its
1732 receptor in its destined compartment. The Ran loop is then
1733 closed by RanGEF (guanine nucleotide exchange factor), which
1734 catalyzes the recharging of RanGDP to RanGTP.301 In this
1735 manner, the Ran gradient acts as a molecular ratchet that
1736 accumulates nuclear cargoes against a concentration gra-
1737 dient.302
1738Given that the size of a legitimate Kap−cargo complex far
1739exceeds the passive transport limit, it is generally accepted that
1740a molecular gating mechanism acts within the NPC that
1741simultaneously promotes the selective translocation of Kap−
1742cargoes while hindering passive cargoes.303 Since their
1743discovery,304 the FG Nups have been identiﬁed as the key
1744functional constituents of the NPC gating mechanism given
1745that their FG-repeat motifs (i.e., GLFG, FxFG, and FG) exert
1746binding interactions with the Kaps.295,305−307 Altogether there
1747are 11 distinct FG Nups308 that line the central NPC channel
1748from the cytoplasmic periphery to the central plane till the
1749distal ring of the nuclear basket. These give rise to an estimated
1750total of ∼200 FG Nup molecules291 that populate the NPC
1751interior based on their relative abundance and the presence of
1752both symmetric (i.e., found on both the nuclear and the
1753 f13cytoplasmic peripheries) and nonsymmetric FG Nups (Figure
1754 f1313). Each FG Nup is tethered to the inner wall of the NPC by
1755an anchor domain from which the remaining FG-rich domain
1756(typically 200−700 residues in length) emanates to occupy the
1757aqueous space within the central channel.292 Presently, the
1758exact location of each FG Nup tethering site is known with a
1759precision of approximately ±10 nm in the NPC.282,309
17603.3.2. Intrinsic Disorder in FG Nups. Initial indications of
1761their intrinsic disorder originated from the analysis of amino
1762acid composition, which indicated that the yeast S. cerevisiae FG
1763Nups possessed high net charge and low overall hydrophobicity
1764due to a low presence of order conferring amino acids (N, C, I,
1765L, F, W, Y, V) and an enrichment of disorder-conferring amino
1766acids (A, R, Q, E, G, K, P, S).51 This was validated by
1767spectroscopic measurements (e.g., circular dichroism (CD))
1768showing that the FG Nups lacked ordered secondary
1769structure,310 which was consistent with their large hydro-
1770dynamic dimensions. Later, it was shown that the FG Nups
1771with low charge content adopted more disordered conﬁg-
1772urations, whereas those with high charge content adopt more
1773extended conﬁrmations.311 Indeed, most FG Nups are net
1774positively charged,311−313 and can adopt conformations within
1775the NPC that might expose these charged regions to attract
Figure 13. Intrinsically disordered FG Nups ﬁll the NPC. Estimated
abundances (numbered) and FG Nup positions in S. cerevisiae. Each
FG Nup is tethered on one terminal end to the inner walls of the NPC
by an anchor domain from which the remaining FG-rich domain
emanates to occupy the aqueous space within the central channel.
Some FG Nups are symmetric (green), while others are exclusively
cytoplasmic (red) or nuclear (blue). For clarity, each FG Nup varies in
length, sequence, and number/type of FG-repeats (superscript). Error
bars denote uncertainty with respect to their exact anchoring sites.
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1776 more negatively charged Kaps, while repelling positively
1777 charged cargoes. Nevertheless, biochemical analyses as well as
1778 in vivo studies generally show that FxFG domains exhibit “non-
1779 cohesive” properties,314,315 while GLFG domains are more
1780 cohesive.314,315
1781 3.3.3. Conformational Behavior of FG Nups.
1782 3.3.3.1. FG-Hydrogels. Being intrinsically disordered, the FG
1783 Nups still elude structural/conformational determination inside
1784 the NPC, although their positional information has been
1785 obtained indirectly by immunogold labeling microscopy278,309
1786 or via ﬂuorescence.316,317 Thus, our understanding of FG Nup
1787 behavior is dominated by in vitro investigations. Nevertheless,
1788 FG Nup “non-cohesion” or “cohesion” has led to the idea that
1789 NPC barrier functionality largely derives from their collective
1790 morphological characteristics.303 At the macroscopic scale,
1791 studies show that both FxFG and GLFG Nup-types can cohere
1792 into hydrogels using nonphysiological chemical treat-
1793 ments.318,319 This is based on the notion that the FG Nups
1794 might resemble a sieve-like meshwork or “selective phase”
1795 within the NPC based on hydrophobic interactions between
1796 neighboring FG-repeats.318 Indeed, mild apolar solvents (e.g.,
1797 hexanediol) could cause a reversible collapse in the FG Nup
1798 barrier by perturbing the hydrophobic inter-FG interactions.
1799 These FG-hydrogels show to reproduce the permeability
1800 properties of the NPC provided that the gels are saturated;
1801 that is, every FG-repeat participates in a cross-link. The
1802 selective phase model predicts that the spacing between each
1803 mesh (estimated to be between 3 and 6 nm based on the length
1804 of one repeat unit) deﬁnes the size limit for free diﬀusion
1805 through the hydrogel. Selective transport may then occur
1806 through catalytic binding of the Kap to individual FG-repeats
1807 that would eﬀectively break individual cross-links. It is not clear,
1808 however, how these macroscopic hydrogel properties relate to
1809 the behavior of ∼200 FG Nups in the NPC given the marked
1810 diﬀerences between length scales, the in vitro requirements for
1811 gelation, and in vivo conditions in the cell.
1812 3.3.3.2. Polymer Brush Behavior. In contrast to hydrogels
1813 that congeal from FG Nups in solution, the NPC interior
1814 presents many FG domains that a priori form a tethered layer
1815 in close proximity to one another. Because of their inherent
1816 ﬂexibility,320 the FG Nups are anticipated to exhibit a
1817 conformational susceptibility to local interfacial constraints,
1818 which should have a strong inﬂuence on their biophysical
1819 characteristics. Adopting approaches from polymer/surface
1820 science, atomic force microscope (AFM) force measurements
1821 show that FxFG Nups exhibit polymer brush-like behavior
1822 when surface-tethered to 100 nm gold nanostructures.320,321 By
1823 deﬁnition, polymer brushes are composed of end-tethered
1824 polymeric chains that extend in a net perpendicular direction
1825 away from a surface under dense packing conditions in a good
1826 solvent.322 In this way, polymer brushes resist nonspeciﬁc
1827 adsorption and material accumulation due to an exponential,
1828 long-range repulsive force that is generated upon compression
1829 of the brush.323 With regards to the NPC, brush-like FG Nups
1830 could collectively give rise to a corona-like barrier that would
1831 entropically exclude nonspeciﬁc cargoes from the NPC vicinity,
1832 as was ﬁrst proposed by the virtual gating model.324 This may
1833 also explain why the NPC does not clog under physiological
1834 conditions. Interestingly, the FxFG Nup brushes also exhibit a
1835 reversible collapse under the inﬂuence of poor solvents (i.e., 5%
1836 hexanediol).320
1837 3.3.4. Models of NPC Barrier Action. Comprehensive in
1838 vitro microbead binding assays (i.e., “bead halo”) show that the
1839FxFG Nups are noncohesive as compared to the cohesive
1840GLFG Nups.314,325 By correlating these properties to their
1841estimated locations in the NPC, the “two-gate” model proposes
1842that the central channel is occupied by cohesive meshwork-
1843forming GLFG Nups, whereas the peripheral FxFG Nups are
1844brush-like. However, further experimental/computational re-
1845ﬁnements have shown that cohesive or extended noncohesive
1846domains can coexist on diﬀerent segments along a single FG
1847Nup depending on their charge content.311 This might deﬁne a
1848particular barrier arrangement (i.e., “forest and trees” model)
1849that demarcates distinct zones of traﬃc through the NPC.
1850These contrasting properties of the FG domains may
1851dominate the basis of mechanistic “FG-barrier centric” models;
1852however, explanations as to how Kaps bypass the barrier remain
1853phenomenological. As a ﬁrst step to understanding how this
1854might proceed, it was observed within the NPC by immuno-
1855labeling electron microscopy and in vitro by biophysical AFM
1856measurements that Kapβ1−FG binding causes a collapse of
1857brush-like FG Nups.321 The FG Nup collapse could be
1858subsequently reversed upon the introduction of RanGTP,
1859which prevented further binding of the Kapβ1 molecules to the
1860FG Nups. This suggested that Kap (un)binding causes the FG-
1861domains to undergo transient conformational changes, such as
1862by collapsing and distending in a rapid, stochastic manner
1863during cargo transport.321 Yet, it has been suggested that the
1864FG Nups are in a perpetual state of collapse at physiological
1865Kap concentrations in the NPC.326 According to the “reduction
1866of dimensionality” (ROD) model,327−329 the collapsed FG-
1867domains could eﬀectively coat the walls of the central channel
1868with a coherent hydrophobic “FG-rich layer” that would
1869promote the surface diﬀusion of Kap−cargo complexes. This
1870implies that an unoccluded space at the central channel would
1871allow small molecules to permeate through.
1872Very little is known beyond such ﬁgurative descriptions of
1873possible NPC barrier entry mechanisms at the molecular level.
1874Given that NPC rejection is a consequence of weak
1875(nonspeciﬁc) binding implies that selective translocation
1876requires suﬃcient Kap−FG binding to cause a transient breach
1877or opening in the FG domain barrier. Here, each Kapβ1
1878molecule consists of approximately 10 hydrophobic grooves
1879that can all potentially bind FG-repeats.295,330,331 Kap−FG Nup
1880binding is therefore characterized by highly multivalent
1881interactions303 because each FG Nup contains between 5 to
1882around 50 FG-repeats in vertebrates. This raises a paradox in
1883the context of the NPC, because multivalent interactions are
1884generally known to impart strong binding avidity that enhances
1885stability and speciﬁcity.332 As a case in point, the high sub-
1886micromolar Kapβ1−FG domain binding aﬃnities330,333−335
1887predict slow transport rates336 that contradict the rapid dwell
1888time of ∼5 ms measured in vivo.337 In fact, synthetic nanopores
1889constructed by functionalizing polymeric membranes with the
1890FG Nups show to recapitulate the selective transport of Kaps
1891and Kap−cargo complexes while discriminating against non-
1892speciﬁc proteins.338 Subsequently, biomimetic NPCs con-
1893structed by covalently tethering the FG Nups to solid-state
1894silicon nitride nanopores were able to resolve Kap selectivity
1895and translocation at the single-molecule level using ionic
1896current measurements.339 Notably, it was found that individual
1897Kapβ1 molecules translocated with a dwell time of ∼2.5 ms, in
1898close agreement with known NPC values.337 Moreover, the FG
1899Nups strongly inhibited the passage of nonspeciﬁc proteins in
1900pores having diameters greater than 25 nm despite adopting a
1901more open structure, thereby alluding to a highly dynamic FG
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1902 domain barrier mechanism. Yet, insofar as these eﬀorts go, it
1903 remains unexplained how Kap−FG interactions promote fast
1904 translocation in the NPC instead of slowing it down.
1905 3.3.5. FG Barrier-Centric Paradigm. The criteria for the
1906 FG-centric paradigm can be summarized as follows:
1907 (i) The FG Nups should act collectively as a barrier that
1908 imposes a ∼40 kDa limit on passive diﬀusion, for example,
1909 “hydrophobic meshwork”,318,319 “polymer brush”,320,321 and
1910 “two gate/forest and trees”.311,314
1911 (ii) Karyopherin receptors that ferry NLS-cargo must bind
1912 suﬃciently to the FG Nup barrier to ensure selectivity. This is
1913 because insuﬃcient binding (e.g., nonspeciﬁc cargoes) implies
1914 rejection.334,340
1915 (iii) Kap binding has to cause FG Nup conformational
1916 changes to alleviate spatial constraints imposed by the barrier,
1917 for example, “meshwork melting”,318,319 “reversible col-
1918 lapse”.320,321
1919 (iv) High Kap mobility is required; that is, single-molecule
1920 ﬂuorescence shows that in vivo transport dwell times are ∼5
f14 1921 ms.337
1922 Although each argument per se is rational, apparent
1923 contradictions emerge when all four arguments are imposed
1924 on the NPC. It is particularly diﬃcult to reconcile Kap−FG
1925 binding kinetics with the mechanistic control of the FG domain
1926 barrier. As a case in point, suﬃciently strong Kap−FG binding
1927 might ensure transport selectivity, but how this promotes rapid
1928 in vivo translocation is not obvious.336 In fact, selective
1929 transport should essentially slow down in FG-centric models.
1930 3.3.6. Emergence of a Kap-Centric Barrier Mechanism.
1931 To provide insight into this problem, most recently a novel
1932 surface plasmon resonance method was used to directly
1933 correlate conformational changes of surface-tethered FG
1934 Nups to multivalent Kapβ1−FG binding interactions (i.e.,
1935 binding avidity) in situ as a function of FG Nup surface
1936 density.341 Stepwise measurements at increasing Kap concen-
1937trations showed that FG Nup collapse321 accompanied strong
1938Kap binding (KD ≲ 1 μM) at low concentrations, but gradually
1939re-extended or “self-healed” as the population of bound Kaps
1940increased at higher concentrations. Interestingly, this eﬀect has
1941been observed in computational models,342,343 and invalidates
1942the idea that the FG Nups are in a perpetual state of
1943collapse327−329 at physiological Kap concentrations. Instead,
1944“pile-up” was observed where Kaps could bind weakly (KD ≳ 10
1945μM) to the top of preoccupied FG domain layers at
1946physiological Kap concentrations (∼20 μM). These ﬁndings
1947predict the existence of multiphase binding in the NPC; that is,
1948strongly bound Kaps populate the FG Nups and move slowly
1949near the pore wall, whereas weakly bound Kaps located close to
1950 f15the pore center translocate more quickly (Figure 15). Indeed,
1951striking similarities have been observed in single-molecule
1952ﬂuorescence experiments that have resolved the preferred
1953localization of Kapβ1 in the NPC.344,345 In this manner, Kap−
1954FG binding can be suﬃciently strong to ensure selectivity but
1955also weak enough to promote fast translocation through the
1956NPC. In fact, the high occupancy of Kaps within the FG Nups
1957has now led to the idea that the Kaps may constitute integral
1958constituents of the NPC barrier,341 which might suggest that a
1959Kap-centric barrier mechanism rather than a FG domain-centric
1960one regulates transport selectivity and speed through the
1961NPC.346
19623.3.7. The NPC Meets Material Science. To summarize,
1963the exact manner by which the FG Nups contribute to the NPC
1964gating mechanism still remains unclear. This arises from the
1965general diﬃculty in ascertaining the collective FG Nup behavior
1966within the NPC in vivo, and their sensitivity to experimental
1967design and length scale in vitro. Like any complex material,
1968what is clear is that the FG Nups, being intrinsically disordered,
1969can adopt diﬀerent morphologies and exist in varied forms with
1970diverse structures and characteristic properties. This can range
1971from single molecules in solution,311,347 to the collective
1972behavior of surface-tethered FG Nups,320,321,341 to the
1973formation of amyloids,348,349 and macroscopic FG Nup
Figure 14. FG-centric NPC models. In this paradigm, the barrier
mechanism is composed solely of FG Nups. Selective access is
exclusive to Kaps (green) that bind the FG-repeats via multivalent
interactions. Large nonspeciﬁc molecules (large red) are withheld due
to insuﬃcient binding with the FG-repeats. Small molecules (small red
watermarked) diﬀuse freely through the barrier.
Figure 15. Kap-centric NPC model. Because of strong binding avidity,
large numbers of Kap molecules are accommodated with the FG Nups.
Slow Kaps that reside within the FG Nups (dark green) form integral
barrier constituents. Weakly bound Kaps (light green) dominate fast
transport due to limited penetration into the preoccupied FG Nups.
Large nonspeciﬁc molecules (large red) are excluded from the pore.
Small molecules (small red watermarked) diﬀuse freely through the
barrier.
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1974 hydrogels.318,319 Although they all consist of FG Nups, it would
1975 be unrealistic to presuppose that each of these higher order
1976 structures would be physico-chemically similar or functionally
f16 1977 comparable because they are diﬀerent materials (Figure 16).
1978 Hence, in vitro, it remains essential to consider the contextual
1979 details and the physical constraints within the NPC that
1980 underpin FG Nup behavior there. To illustrate this point, it is
1981 diﬃcult to establish direct morphological and functional
1982 correlations between a macroscopic FG Nup “material” and
1983 the NPC permeability barrier (nanoscopic). Being several
1984 orders of magnitude larger in size, a hydrogel itself can consist
1985 of several diﬀerent higher order structures and phases with
1986 distinct materials properties. Indeed, structural microanalysis
1987 has recently revealed that FG Nup hydrogels are comprised of
1988 several submicrometer-sized channels enmeshed within a
1989 structurally complex network of amyloid ﬁbers (e.g., “Swiss
1990 cheese”).350 As depicted in Figure 16, it is possible that each
1991 submicrometer channel may contain surface-tethered FG Nups
1992 such that it resembles and imparts NPC-like functionality to the
1993 hydrogel. Conversely, surface-tethered FG Nups are physically
1994 constrained, unlike single molecules in solution. Last, the NPC
1995 barrier may very well resemble a composite material given that
1996 the high Kap occupancy may signiﬁcantly alter the FG Nup
1997 characteristics. Therefore, the challenge is not to simply
1998 understand FG Nup behavior alone, but rather to resolve
1999 how Kap binding and occupancy alters the physicochemical
2000 properties of the FG Nups under conditions and length scales
2001 that are compatible with the NPC.
3.4. Intrinsic Disorder in the Ribonucleoprotein Complexes
2002 3.4.1. Intrinsically Disordered Histones and Nucleo-
2003 some. RNA- and DNA-binding proteins are enriched in
2004 intrinsic disorder,2,3,6,8 with many nuclear proteins being IDPs
2005 involved in the regulation of transcription and cell signaling,36
2006 and with many transcription factors being either completely
2007 disordered or containing long IDPRs.115,351,352 Disorder is also
2008 very common in the histone family of small, highly basic
2009 nuclear proteins that associate with DNA in a speciﬁc
2010 stoichiometry to form the nucleosome, the basic unit of
2011 DNA packaging in eukaryotes. Histone family in mammals has
2012 ﬁve classes, core histones H2A, H2B, H3, H4, and a linker
2013 histone H1, which is substituted by a histone H5 in avian
2014 erythrocytes containg nucleus. These histone classes are further
2015 divided into multiple subclasses, each containing numerous
2016 variants expressed in a cellular context-dependent manner.
2017 Being responsible for the DNA condensation in chromatin,
2018 histones are involved in major cellular processes, such as DNA
2019damage response, X chromosome inactivation, transcriptional
2020regulation, and even formation of an epigenetic memory.353−360
2021The activity of histones is intimately regulated via the broad
2022range of reversible, enzymatically catalyzed posttranslational
2023modiﬁcations (PTMs) constituting a speciﬁc histone
2024code.361−365 Several diseases and syndromes are related to
2025the dysregulation of histone functions and PTMs.366
2026Formation of chromatin is a very eﬃcient way of DNA
2027condensation and packing inside the cell nucleus, which allows
2028the almost 2 m-long human DNA to be condensed to ﬁt inside
2029a nucleus with a diameter of only 5−10 μm.367 This high
2030degree of DNA condensation is achieved via DNA interaction
2031with histones to form the speciﬁc “beads on a string” structure,
2032where each “bead” is the nucleosome core particle that typically
2033contains about twice as much protein as DNA.368 The
2034eukaryotic nucleosome core particle contains 146 base pairs
2035of DNA, wrapped 1.65 times around a histone core octamer
2036consisting of two dimers of H2A−H2B that serve as molecular
2037caps for the central (H3−H4)2 tetramer, whereas the H1
2038histone binds to the DNA as it enters each nucleosome core
2039particle.367
2040As with other proteinaceous machines, the nucleosome does
2041not represent a simple and static packaging system, being a
2042dynamic regulator of DNA chemistries in the nucleus, including
2043transcription, replication, and repair.369,370 This dynamic
2044regulation is achieved via the modiﬁcation of stability, structure,
2045and association state of the core nucleosome proteins. The
2046crucial regulatory roles of intrinsic disorder in the nucleosome
2047function were recognized long time ago, because the tails of all
2048four core histones are known to be IDPRs371 containing sites of
2049numerous and various PTMs.361,372 In fact, reversible lysine
2050acetylation and serine phosphorylation of the histone tails at
2051speciﬁc positions are known to modulate the structure of
2052chromatin,361,372 and the histone tail-mediated internucleoso-
2053mal attraction and control of the chromatin conformation
2054through site-speciﬁc posttranslational modiﬁcations constitute
2055the basis of the histone code hypothesis.361−365 Here, a speciﬁc
2056combination of PTMs at the histone tails aﬀects the chromatic
2057structure and serves as a sectrete code responsible for the
2058generation of diverse and controllable biochemical responses by
2059switching various gene transcription and other signaling events
2060on or oﬀ.371
2061Intrinsic disorderedness of the histone tails follows directly
2062from their speciﬁc amino acid compositions. In fact, the N-
2063terminal tails are the most basic regions of the core histones, as
2064they contain no acidic residues, and include 38 and 45 mol %
2065basic residues, for H2A and H2B, respectively.373 Furthermore,
Figure 16. The FG Nups exhibit a rich material complexity. In vitro FG Nup behavior is sensitive to experimental design and length scale.
Depending on the context, the FG Nups can exhibit diﬀerent morphologies and materials properties, which can assemble into higher order
structures. For instance, macroscopic hydrogels consist of several porous channels enmeshed within a scaﬀold provided by amyloid ﬁlaments. Each
porous channel may be lined with FG Nups that bestows the hydrogel NPC-like functionality, as is the case for FG Nups tethered to artiﬁcial
nanopores. See text for details.
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2066 in crystal structures, the C-terminal sequences of H2A and H2B
2067 histones extend beyond the histone fold, with the H2A C-
2068 terminal 31 residues adopting the largely extended conforma-
2069 tion, and with the H2B C-terminal extension of 23 residues
2070 being predominantly helical.374 The highly dynamic nature of
2071 histone tails is further visualized by the X-ray structures of
2072 nucleosomes where tail domains appear to sample multiple
2073 conformations.374,375 Although the core histones typically
2074 contain ﬂexible N-terminal tails that are not completely
2075 resolved in the X-ray crystal structure of the core
2076 nucleosome,374 some histone tails are able to adopt speciﬁc
2077 structures being bound to a linker DNA or to the acidic patches
2078 of core histones.376−378 Circular dichroism and a combination
2079 of hydrogen exchange with NMR experiments revealed that
2080 H4/H3 tails acquire structured conformations as part of
2081 nucleosome core particles, whereas H2A and H2B are
2082 essentially disordered.378−380 The intrinsically disordered
2083 nature of the N-terminal “tail” domains (NTDs) of the core
2084 histones and the C-terminal tail domains (CTDs) of linker
2085 histones (which make up ∼28% of the mass of the core histone
2086 proteins), peculiarities of their amino acid compositions, and
2087 the role of disorderedness in functioning and posttranslational
2088 modiﬁcations of these domains were systemized in a review by
2089 Hansen et al.381
2090 Structural and functional properties of the core histones
2091 H2A, H2B, H3, and H4 and members of a linker histone family
2092 (H1) and conformational behavior of these important proteins
2093 are the subject of intensive research.382 Curiously, although the
2094 crystal structure of the nucleosome core particle has been
2095 solved,374,383 pure histones dissolved in water with no added
2096 salt are in an “extended loose form”.384−392 Systematic
2097 structural characterization of a mixture of calf thymus core
2098 histones H2A, H2B, H3, and H4, revealed that these proteins
2099 are typical IDPs with extremely high conformational plasticity
2100 that determines their ability to fold diﬀerently on a condition-
2101 dependent manner.393
2102 The analysis of the crystal structure of the histone core
2103 particle from X. laevis revealed that the NTDs of both H3 and
2104 H2B have random-coil segments passing between the gyres of
2105 the DNA superhelix, whereas the two H4 NTDs have diﬀerent
2106 structures.374 Also, only about one-third of the total length of
2107 the histone NTDs and CTDs is seen in the electron density
2108 map,374 suggesting that the remainders of tails are highly
2109 disordered. Careful analysis of the nucleosome crystal structure
2110 revealed that the disorderedness goes far beyond the histone
2111 tails.394 In fact, the step-by-step computational dissection of the
f17 2112 nucleosome core particle (see Figure 17) revealed that the
2113 shapes of individual histone proteins are highly unusual for
2114 typical globular proteins. In fact, even a brief glance at the
2115 nucleosome crystal structure reveals that histones possess long
2116 disordered regions, seen as extended tails protruding from the
2117 core structure (see Figure 17A). These extension and
2118 protrusions become more evident when DNA chains are
2119 taken out (Figure 17B). Analysis of the H2A−H2B dimers
2120 (Figures 17C1 and C2), the (H3−H4)2 tetramer (Figure 17D),
2121 and two H3−H4 dimers (Figure 17D1 and D2) shows that
2122 these elementary subcomplexes of the nucleosome core particle
2123 possess globular cores that are heavily decorated with
2124 protrusions. The subsequent visual inspection indicates that
2125 the individual histone proteins, H2A (Figure 17C1a and C2a),
2126 H2B (Figure 17C1b and C2a), H3 (Figure 17D1a and D2a),
2127 and H4 (Figure 17D1b and D2b), possess very unusual shapes
2128 and are almost complete devoid of the globular structure. These
2129peculiar shapes suggest that histones are disordered in the
2130unbound states and form the two-state (or disordered)
2131complexes via binding-induced folding process.394 One should
2132remember however that many histones do not completely fold
2133at interaction with the binding partners, forming instead fuzzy
2134complexes. Furthermore, the computational analyses of >2000
2135histones suggested that the majority of the histone family
2136members are mostly disordered proteins, with intrinsic disorder
2137extending far beyond the limits of mentioned NTDs of the core
2138histones and CTDs of linker histones.394 This bioinformatics
2139study also indicated that intrinsic disorder is not only abundant
2140in histones, but is absolutely necessary for various histone
2141functions, starting from heterodimerization to formation of
2142higher order oligomers, to interactions with DNA and other
2143proteins, and to posttranslational modiﬁcations.394
21443.4.2. Spliceosome: Disordered Ribonucleoprotein
2145Machine for Splicing. One of the characteristic features of
2146the eukaryotic genes is their mosaic architecture with
2147alternating coding and noncoding regions, exons and introns.
2148Because of this peculiar structure, the maturation of the
2149eukaryotic mRNA (mRNA) includes splicing of the pre-mRNA
Figure 17. Structural dissection of the X. laevis nucleosome core
particle (PDB ID: 1AOI). (A) Complete nucleosome core particle
wrapped in DNA (double white-pink ribbon). (B) The nucleosome
core particle after the DNA removal. (C1 and C2) H2A−H2B dimers.
(C1a) and (C1b) represent histones H2A (gray) and H2B (orange) of
the ﬁrst H2A−H2B dimer, whereas (C2a) and (C2b) show histones
H2A (silver) and H2B (green) of the second H2A−H2B dimer. (D)
(H3−H4)2 tetramer. (D1 and D2) H3−H4 dimers. (D1a) and (D1b)
represent histones H3 (blue) and H4 (red) of the ﬁrst H3−H4 dimer,
whereas (D2a) and (D2b) show histones H3 (yellow) and H4 (tan) of
the second H3−H4 dimer. All of these structures were visualized using
the VMD software.509
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2150 at splice junctions found at the extreme ends of each and every
2151 intron, leading to the removal of introns and joining of exons.
2152 There are multiple ways of how exons are joined during the
2153 RNA splicing. Some exons are constitutively spliced and are
2154 present in every mRNA produced from a given pre-mRNA.
2155 Other exons are nonconstitutively spliced and are only present
2156 in a subset of mRNAs produced from a given pre-mRNA,
2157 providing a basis for alternative splicing, a process that generate
2158 variable forms of mRNA from a single pre-mRNA species.
2159 These alternative splicing events are commonly found in many
2160 eukaryotes (e.g., ∼95% of multiexonic genes in humans are
2161 alternatively spliced),395 where they contribute to the increased
2162 proteome diversity,396,397 because by this mechanism a single
2163 gene may code for multiple proteins. On the other hand,
2164 aberrant pre-mRNA splicing and distorted alternative splicing
2165 constitutes the basis of some human diseases or contributes to
2166 the severity of other human maladies.398−400
2167 Pre-mRNA splicing is found in all eukaryotic organisms
2168 investigated to date, where it is typically done by a special
2169 proteinaceous machine, multimegadalton ribonucleoprotein
2170 (RNP) complex known as spliceosome.401,402 The canonical
2171 assembly of the spliceosome occurs anew on each pre-mRNA
2172 that contains speciﬁc sequence elements (such as the 5′ end
2173 splice, the branch point sequence, the polypyrimidine tract, and
2174 the 3′ end splice site) that are recognized and utilized during
2175 spliceosome assembly. Two spliceosome types, the major and
2176 the minor spliceosomes, are known. The major spliceosome is
2177 responsible for removing the vast majority of pre-mRNA
2178 introns. This machine is composed of ﬁve small nuclear RNPs
2179 (snRNPs), the U1, U2, U4/U6, and U5 snRNPs, each of which
2180 contains a corresponding small nuclear RNA (snRNA)
2181 molecule (U1, U2, U4, U5, or U6), and a number of core
2182 proteins. The minor spliceosome is present in some metazoan
2183 species and plants. In addition to the U5 snRNP, which is
2184 shared between the machineries, the minor spliceosome
2185 contains the compositionally distinct but functionally analogous
2186 U11/U12 and U4atac/U6atac snRNPs.403 A common feature
2187 of all spliceosomal snRNPs except U6 is the presence of seven
2188 mutually related Sm proteins. U6 contains a set of related “like-
2189 Sm” (Lsm) proteins.404 These Sm or Lsm proteins form a ring
2190 structure with the positively charged central hole, where a U-
2191 rich sequence in the corresponding snRNA binds.405,406 These
2192 core structures are further enhanced by 80−150 proteins that
2193 are abundant in the human spliceosome and are essential to the
2194 process of spliceosome-dependent splicing.407
2195 In spliceosome, the snRNA acts as a catalyst, whereas the
2196 spliceosomal proteins and nonspliceosomal pre-mRNA pro-
2197 cessing proteins (Prps) not only hold the RNA in the correct
2198 conﬁguration but also carry out essential recognition,
2199 regulation, and catalytic functions during the assembly of the
2200 spliceosome and in the splicing-related catalytic reac-
2201 tions,408−410 play crucial roles in the selection of intron
2202 substrates during the alternative splicing,411 and have important
2203 functions related to the speciﬁcity, accuracy, and regulation of
2204 the spliceosome.412 These proteins are mostly conserved from
2205 yeast to metazoan.410
2206 The spliceosome conformation and composition are highly
2207 dynamic.413 The spliceosome assembly is an ordered and
2208 tightly regulated process that starts with recognition of the 5′
2209 end of the intron (5′ splice site, 5′ss) of the pre-mRNA by the
2210 U1 snRNP. Next, the U2 snRNP binds to the pre-mRNA’s
2211 branch site, forming complex A. This complex A then binds the
2212 preformed U4/U6·U5 tri-snRNP to produce penta-snRNP
2213complex B, which contains a full set of ﬁve snRNAs in a
2214precatalytic state. Complex B is then activated for catalysis by a
2215major rearrangement of its RNA network and by global changes
2216of its overall structure, where the association of U4 with U6 is
2217destabilized, enabling U6 to isomerize into a base-pairing
2218interaction with U2 to form part of the catalytic center of the
2219spliceosome. This remodeling also includes dissociation of the
2220U1 and U4 snRNAs and binding of a set of speciﬁc proteins
2221leading to the formation of the activated spliceosome (Bact).
2222Step 1 of splicing takes place in catalytically activated complex,
2223B*. Here, the adenosine at the branch site attacks the 5′ss site
2224of the pre-mRNA, generating a cleaved 5′-exon and intron-3′-
2225exon intermediate. Finally, complex C is formed via binding
2226another set of speciﬁc proteins. This complex C catalyzes step 2
2227of splicing, in which the intron is cleaved at the 3′-splice-site
2228(3′ss) with concomitant ligation of the 5′ and 3′ exons.410,413
2229Spliceosome is rather well conserved from yeast to human. In
2230fact, the yeast spliceosome contains the evolutionarily
2231conserved core set of spliceosomal proteins that are required
2232for the constitutive splicing to occur.410 However, the number
2233of proteins found in the yeast B, Bact, and C complexes is
2234noticeably lower than the number of spliceosomal proteins in
2235the metazoan complexes.410,413 For example, there are only
2236∼60 proteins in the yeast precatalytic B complexes (as
2237compared to ∼110 in humans and D. melanogaster
2238spliceosomes).410 Similarly, the yeast C complexes contain
2239only ∼50 proteins as compared to ∼110 in the metazoan C
2240complexes.410 The reduced proteome of the yeast spliceosome
2241suggests that the mRNA splicing in yeast is simpler than that in
2242the metazoan. Many of the proteins found in human and D.
2243melanogaster spliceosomes but not detected in yeast play a role
2244in alternative splicing, a process that is essentially absent in
2245yeast.410
2246Bioinformatics analysis of the yeast414 and human
2247spliceosomes415 revealed that despite the fact that the sequence
2248homology between the yeast and human spliceosomal proteins
2249ranges from 36% to a little over 50%,416 the spliceosomal
2250proteins of both species are highly enriched in intrinsic
2251disorder. This suggests that the predisposition for intrinsic
2252disorder is an evolutionary conserved feature crucial for the
2253multiple functions ascribed to the spliceosomal proteins. In
2254agreement with this hypothesis, the bioinformatics analysis of
2255the correlation between the Swiss-Prot functional keywords and
2256protein intrinsic disorder clearly showed that mRNA processing
2257and mRNA splicing were among the 20 top biological processes
2258associated with protein intrinsic disorder.21 Furthermore, the
2259functional keyword “spliceosome” was among the top 20
2260cellular components strongly correlated with predicted
2261disorder.23 Also, there are several case studies, where intrinsic
2262disorder was found in some spliceosomal proteins. For
2263example, NMR analysis revealed that the ﬂanking N- (residues
22641−20) and C-terminal regions (residues 100−125) of the
2265protein p14 (which is a subunit of the essential splicing factor
22663b (SF3b) present in both the major and the minor
2267spliceosomes,417−419 and which is located near the catalytic
2268center of the spliceosome and is responsible for the ﬁrst
2269catalytic step of the splicing reaction419,420) are disordered.421
2270Serine/arginine-rich (SR) splicing factors are important
2271spliceosomal IDPs, which, besides their signiﬁcance for both
2272constitutive and alternative splicing,422 play key roles in the
2273spliceosome assembly by facilitating recruitment of compo-
2274nents of the spliceosome via protein−protein interactions423
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2275 that are potentially mediated by the disordered SR domains of
2276 these splicing factors.424
2277 3.4.3. Flexible Fossil: Ribosome. Protein translation is a
2278 process of protein biosynthesis from individual amino acids
2279 delivered by tRNAs (tRNAs) using mRNA as a template. This
2280 is one of the most central biosynthetic processes present in all
2281 living organisms. The process is catalyzed by a large RNP,
2282 ribosome, which is divided into two subunits, large and small,
2283 each with the set of well-deﬁned functions. Among the
2284 functions of the small subunit are binding and decoding of
2285 the mRNA (this subunit contains the decoding center, which
2286 monitors the complementarity of tRNA and mRNA in protein
2287 translation), whereas the major functions of the large subunit
2288 are binding of the tRNA, and the actual calaysis of the
2289 polypeptide synthesis (this subunit contains the active site of
2290 the ribosome, that acts as the ribozyme by using the speciﬁc
2291 rRNA (rRNA) nucleotides to catalyze chemical reaction of the
2292 peptide bond synthesis).
2293 Although ribosomes are responsible for the synthesis of
2294 proteins across all kingdoms of life, and although their core
2295 functions are mRNA decoding and catalysis of the peptide
2296 bond formation,425 many other translation-related processes
2297 (such as initiation, termination, and regulation) are diﬀerent in
2298 diﬀerent domains of life.426,427 This is reﬂected in the
2299 noticeable diﬀerences between the prokaryotic and eukaryotic
2300 ribosomes. The prokaryotic ribosomes are the 70S RNP
2301 particles with the small and large subunits of 30S and 50S,
2302 respectively. The small 30S subunit contains a 16S rRNA and
2303 21 proteins, whereas the large 50S subunit possesses two
2304 rRNAs (5S and 23S) and 31 proteins. Eukaryotes have a larger
2305 ribosome (80S) consisting of the 40S (small) and the 60S
2306 (large) subunits. The small subunit is comprised of a single 18S
2307 rRNA and 33 proteins, whereas the eukaryotic 60S subunit is
2308 composed of three rRNAs (5S rRNA, 28S rRNA, and 5.8S
2309 rRNA) and 46 proteins.428 Of the 79 eukaryotic ribosomal
2310 proteins, 32 have no homologues in bacterial or archaeal
2311 ribosomes, and those that do have homologues possess long
2312 eukaryote-speciﬁc extensions.429
2313 Ribosomal proteins, with their unique functional and
2314 structural properties, are an intriguing family of the RNA-
2315 binding IDPs that are involved in interaction with both RNA
2316 and other proteins. In addition to being a crucial structural part
2317 of a ribosome, many ribosomal proteins are involved in
2318 translational regulation via binding to operator sites located on
2319 their own mRNAs.430 On the other hand, some ribosomal
2320 proteins (e.g., S16, L15, L16, L20, and L24) are mostly
2321 essential for the assembly of the RNP particle and are
2322 dispensable for function after the ribosomal subunits are fully
2323 assembled,431 suggesting that their major function in the
2324 assembled ribosome is related to the improvement of the
2325 ribosome stability. Among the various on-ribosome ﬁnctions of
2326 the ribosomal proteins are the delivery of the mRNA into the
2327 proximity of the ribosome during initiation (S1), formation of
2328 the mRNA entry pore (S3, S4, and S5), some helicase activity
2329 to unwind mRNA during translation (S3, S4, and S5), decoding
2330 and control of the ﬁdelity of translation (S4, S5, and S12),
2331 release and binding of tRNAs to the ribosome (L1 and L16/
2332 L27), elongation-factor binding and GTPase activation (L7/
2333 L12), interaction with nascent chains to control translation of
2334 particular proteins (L22), regulation of the tRNA stability at the
2335 P site (L9), regulation of the mRNA movement (L9),
2336 controlling of the eﬃciency of the translational bypassing
2337 (L9), etc. Besides these and many other on-ribosome functions
2338that were covered in a recent in-depth review,432 many
2339ribosomal proteins were shown to act as moonlighting proteins,
2340being involved in numerous extra-ribosomal or auxiliary
2341functions.18,433−437 The multitude of extra-ribosomal functions
2342of ribosomal proteins were grouped into two major categories
2343related to the control of the balance among the ribosomal
2344components and control of the nucleolar stress and aberrant
2345ribosome synthesis leading to the cell cycle arrest or
2346apoptosis.436
2347The facts that many ribosomal proteins are either completely
2348disordered or contain long IDPRs in isolation are known for a
2349long time.2,6 On the basis of the analysis of the crystal
2350structures of ribosome subunits, it was discovered that almost
2351one-half of the ribosomal proteins have globular domains with
2352long extensions that penetrate deeply into the ribosome
2353particle’s core.438−445 It was also indicated that many of the
2354disordered protrusions play important roles in ribosomal
2355assembly,444,446−448 where the long basic extensions of
2356ribosomal proteins (e.g., L3, L4, L13, L20, L22, and L24)
2357penetrate deeply into the ribosome subunit cores, undergo
2358disorder−order transition individually, or cofold with their
2359RNA, thereby facilitating the proper rRNA folding.444 One can
2360argue that in the cell, most of the ribosomal proteins only exist
2361in the bound state and are never found in isolation. However, as
2362discussed above, many ribosomal proteins are moonlighting
2363proteins possessing various extra-ribosomal or auxiliary
2364functions.18,433−437 This suggests that these moonlighting
2365ribosomal proteins might spent some part of their functional
2366life in the noncomplexed form, at least while transitioning from
2367one fucntional state to another. Also, some ribosomal proteins
2368preserve ﬂexibility even in their bound forms (e.g., ﬂexible
2369“stalk” formed by L7/L12 protein449,450). Furthermore, local
2370ﬂexibility provides means necessary for the easy access of the
2371modifying enzymes to the potential PTM sites, which are
2372abundant in some ribosomal proteins (e.g., recent high-
2373throughput proteomics analyses and mapping studies showed
2374that ribosomal proteins and translation factors in mitochondria
2375are commonly phosphorylated and acetylated;451 the S6
2376phosphorylation on ﬁve evolutionarily conserved serine
2377residues is known to occur in response to a wide range of
2378stimuli452).
2379The computational disassembly of the eukaryotic ribosome
2380revealed that almost all ribosomal proteins are characterized by
2381the very unusual shapes inconsistent with simple globular
2382structure, suggesting that many ribosomal proteins are involved
2383in the formation of the two-state (or disordered) complexes.437
2384This conclusion is based on the results of the ribosome
2385structure analysis using the per-residue surface area versus the
2386per-residue interface area plot.64 In this plot, ordered and
2387disordered proteins are separated by a linear boundary, with the
2388components of the disordered complexes formed via a two-
2389state mechanism being distributed sparsely over a broad area in
2390the top-right part of the plot, and with the protomers of the
2391ordered complexes formed via the three-state mechanism being
2392condensed in the small area at the bottom-right corner of the
2393plot.64 Figure 1D represents the per-residue surface area versus
2394the per-residue interface area plot based on the analysis of the
2395eukaryotic ribosome crystal structure, and clearly shows that
2396almost all of the ribosomal proteins are expected to be
2397disordered in their unbound form, being located above the
2398order−disorder boundary.437 These observations suggest that
2399almost all ribosomal proteins are likely to be intrinsically
2400disordered in isolation but fold to a diﬀerent degree upon the
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2401 ribosome formation.437 This hypothesis is in agreement with
2402 the earlier experimental studies, which showed that many
2403 individual ribosomal proteins do not possess ordered structure
2404 in their nonbound forms or at least contain long disordered
2405 regions.2,453−466 Further support to this idea came from the
2406 comprehensive bioinformatics analysis of 3411 ribosomal
2407 proteins from 32 species.437 This analysis revealed that the
2408 vast majority of ribosomal proteins are intrinsically disordered,
2409 and that intrinsic disorder is very important for various
2410 biological functions of these important RNA-binding proteins,
2411 being commonly used as means for the numerous interactions
2412 of any given ribosomal protein with its various binding partners
2413 of diﬀerent nature, such as other ribosomal proteins, RNA, and
2414 proteins from the translational machinery. The intrinsically
2415 disordered nature of ribosomal proteins is highly conserved in
2416 diﬀerent domains of life, indicating that the lack of rigid
2417 structure and the resulting capabilities of the ribosomal proteins
2418 to interact with various binding partners and be involved in the
2419 wide spectrum of the moonlighting activities represent strong
2420 evolutionary advantage.437
2421 Ribosomes are excellent examples of the IDP-rich machines,
2422 where disorder goes far beyond the discussed above extensive
2423 disordered nature of ribosomal proteins. For example, recent
2424 cryo-EM analysis generated a 6.6 Å resolution snapshot of the
2425 last step in eukaryotic initiation, the complex of the 80S
2426 ribosome, Met-tRNAi
Met, mRNA, and initiation factor eIF5B
2427 with the nonhydrolyzable GTP analogue β-γ-methyleneguano-
2428 sine 5′-triphosphate (GDPCP).467 Curiously, this analysis
2429 revealed that only the G-domain and domain II of the initiation
2430 factor eIF5B were clearly visible in the complex, suggesting that
2431 the eIF5B had become partially disordered.467 Also, recent
2432 cryo-EM analysis of the eukaryotic release factor eRF1−eRF3-
2433 associated termination complex containing 80S ribosome,
2434 tRNA, and eRF1−eRF3−GMPPNP complex revealed that
2435 both eukaryotic release factors (eRF1 and eRF3) underwent
2436 dramatic conformational changes as a result of complex
2437 formation, where their domains shifted and rotated substan-
2438 tially as compared to the structures of individual eRF1 and
2439 eRF3.468 Flexibility in linker regions connecting domains of
2440 eRF1 and eRF3 deﬁnes the ability of these factors to contact
2441 both ribosomal units at multiple sites.468 Furthermore, it was
2442 shown that binding of release factors induces conformational
2443 changes in both 40S and 60S subunits aﬀecting the entrance of
2444 the mRNA-binding channel in the 40S subunit and the two
2445 stalks of the 60S subunit.468
3.5. Scaﬀold Proteins: The Pliable Heart of the Signaling
2446 Machines
2447 Among the realm of nonobligate and transient multimers are
2448 various signaling and regulatory complexes characterized by the
2449 presence of special scaﬀold proteins that selectively bring
2450 together speciﬁc proteins within signaling pathways to facilitate
2451 and promote interactions between them. Scaﬀold proteins
2452 inﬂuence cellular signaling by providing specialized binding
2453 platforms for multiple signaling enzymes, receptors, or ion
2454 channels.24,469−472 In essence, scaﬀold proteins represent a
2455 subclass of hubs that, being characterized by a modest number
2456 of interacting partners, provide selective spatial orientation and
2457 temporal coordination to facilitate interactions among bound
2458 partners. In this way, a set of important temporal, spatial,
2459 orientational, and contextual aspects is added, which is crucial
2460 for modulation and regulation of alternative pathways by
2461 promoting interactions between various signaling proteins.24
2462Being located at the heart of the crucial signaling complexes,
2463scaﬀold proteins possess multiple functions, ranging from
2464passive “bringer together” speciﬁc proteins within signaling
2465pathways to providing coordination of alternate signal routes in
2466multiple pathways, to binding simultaneously to multiple
2467participants in a particular pathway to facilitate and/or modify
2468the speciﬁcity of pathway interactions,24,473 to acting on
2469individual proteins by changing their conformation and thus
2470modulating their activity, to acting on interaction partners by
2471providing proximity and spatial orientation, to controlling the
2472relative position between bound partners, to regulating the
2473composition of bound proteins, to creating focal points for
2474spatial and temporal coordination of catalytic activity of
2475signaling enzymes.24,474 Systematic computational analysis
2476revealed that there are several mechanisms by which intrinsic
2477disorder contributes to the functions of scaﬀold proteins.24
2478Some illustrative examples of the advantages of these disorder-
2479based functions of scaﬀold proteins are24 the ability for binding
2480of the modular domains (such as SH2, SH3, or PDZ domains)
2481or the helical repeats (such as armadillo, HEAT, and
2482tetratricopeptide) found in scaﬀold proteins to speciﬁc short
2483linear motifs located in signaling proteins; ability of binding of
2484speciﬁc signaling proteins to the disordered MoRFs located
2485within scaﬀold proteins; ease of encounter complex formation;
2486structural isolation of partners; modulation of interactions
2487between bound partners; ability to mask the intramolecular
2488interaction sites; maximizing interaction surface per residue;
2489toleration of high evolutionary rates; competitive binding due
2490to the binding site overlap; allosteric modulation; suitability for
2491palindromic binding; and eﬃcient regulation via posttransla-
2492tional modiﬁcations, alternative splicing, and rapid degradation.
3.6. Flexibility of Cytoskeleton and Extracellular Matrix
24933.6.1. Intrinsic Disorder and Cytoskeleton. In this
2494section, we consider the roles of intrinsic disorder for function
2495of seemingly rigid proteinaceous machines, cytoskeleton and
2496extracellular matrix. The cytoskeleton is a special proteinaceous
2497intracellular scaﬀolding present within all cells. Among various
2498functions ascribed to this organelle are maintenance of the
2499cellular structure and shape, active roles in intracellular
2500transport (the movement of vesicles and organelles, for
2501example), and cellular division. Although the term “skeleton”
2502implies rigidity, cellular cytoskeleton is characterized by the
2503combination of opposite characteristics, such as stability and
2504dynamics, physical rigidity and ﬂexibility, long-time persistence,
2505and rapid, cataclysmic rearrangements.475 Eukaryotic cytoske-
2506leton is composed of three basic components: microﬁlaments
2507(actin), intermediate ﬁlaments (IFs), or neuroﬁlaments (NFs)
2508in neuronal cells (these are the most heterogeneous part of the
2509cytoskeleton, and depending on a cell type, IFs can be made of
2510vimentin, acidic and basic keratins, desmin, peripherin,
2511neuroﬁlament proteins, syncoilin, lamin, phakinin, and ﬁlensin),
2512and microtubules (MTs, which are the polymerized tubulin α/β
2513heterodimers). The cytoskeleton deﬁnes the physical separation
2514of cellular constituents that provides a special microenviron-
2515ment, segregation, and direction of cellular activities.475
2516Importantly, recent comprehensive computational analysis
2517revealed that many proteins involved in the organization of
2518three major ﬁlamentous networks comprising cytoskeleton, for
2519example, microﬁlaments (actin ﬁlaments), intermediate ﬁla-
2520ments (neuroﬁlaments), and microtubules, are intrinsically
2521disordered or hybrid proteins possessing functionally important
2522disordered regions.475 It was emphasized that these three
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2523 cytoskeletal systems possess a very similar architectural design
2524 with a central repetitive scaﬀold assembled from folded building
2525 elements being surrounded by accessory intrinsically disordered
2526 regions/proteins that regulate formation of this core and
2527 control, regulate, and mediate its interactions with its
2528 environment, and send speciﬁc regulatory signals to and from
2529 the cytoskeleton.475 In fact, proteins in the actin-based
2530 component of the cytoskeleton were predicted to possess, on
2531 average, 30% disordered residues, with many proteins
2532 associated with microﬁlaments (such as tymosin α, β-thymosin,
2533 juxtanodin (or ermin), cordon-blue, epsin, WASP, SCAR/
2534 WAVE, cortactin (EMS1), supervillin, JMY, and spire) being
2535 highly disordered proteins.475 Furthermore, actin itself, being
2536 the major component of the microﬁlaments, was shown to
2537 possess multiple features ascribed to IDPs.476 What is even
2538 more important, microﬁlaments decorated with the intrinsically
2539 disordered actin binding proteins (such as β-thymosin and
2540 Wiskott−Aldrich syndrome protein homology domain 2
2541 (WH2)) represent an important illustration of fuzzy complexes,
2542 where the intrinsic disorder of WH2 and β-thymosin is partially
2543 conserved in the bound state, and where the resulting fuzziness
2544 is needed to assemble and disassemble the actin polymer.477,478
2545 Actin is an enigmatic multifunctional protein. It is found in
2546 almost every living cell, being most common in the muscle
2547 cells, where its concentration ranges from 230 to 960 μM.479
2548 Among various functional and structural features ascribed to
2549 this protein are its ability to bind one divalent cation and one
2550 molecule of ATP (or ADP), the ability to exists in monomeric
2551 form known as G-actin, or a single-stranded polymer, the so-
2552 called ﬁbrous form known as F-actin, or in oligomeric inactive
2553 form that lacks the ability to polymerize and can be produced
2554 by the release of cation by EDTA or EGTA treatment,480−482
2555 among other means. Furthermore, actin is found not only in
2556 the cellular cytoplasm where it participates in the dynamic life
2557 of cytoskeletal microﬁlamets, but within the cell nucleus,483,484
2558 where it can act as a transcription initiator by interacting with
2559 nuclear myosin bound to RNA polymerases and other proteins
2560 related to the transcription process,483 thereby playing crucial
2561 roles in regulation of transcription,485 transcription factor
2562 activity,486 and chromatin remodeling.487
2563 The “functional” forms of actin in the muscle, the cytoplasm
2564 of the nonmuscle cells, and the nucleus are rather diﬀerent. In
2565 the muscle, being assembled, the ﬁlaments are not
2566 disassembled, and new ﬁlaments appear only during the muscle
2567 growth or reparation; therefore, the main functional form of
2568 actin here is F-actin. In the nonmuscle cytoplasm, although the
2569 cytoskeleton is composed of actin ﬁbrils, it can be assembled
2570 and disassembled. Cell motility is also based on actin ﬁlament
2571 polymerization and depolymerization. Therefore, a suﬃciently
2572 large amount of actin monomers must be stored in the
2573 cytoplasm to support the eﬀective function of actin. In the
2574 nucleus, for the ﬁrst time, actin monomers play a signiﬁcant
2575 role by regulating the serum response factor activity. The actin
2576 monomer pool is involved in controlling the expression of
2577 many proteins that are themselves components of the actin
2578 cytoskeleton.485 Besides, actin is characterized by a very unusual
2579 unfolding mechanism (unfolding with a trap), where the
2580 formation of the transition state N* precedes the trans-
2581 formation of the native actin into the essentially unfolded form
2582 (U*). The formation of this essentially unfolded state (U*)
2583 precedes the formation of completely unfolded (U) or
2584 inactivated actin (I). In the processes of folding and unfolding,
2585 the essentially unfolded state (U*) is an on-pathway
2586intermediate, whereas inactivated actin (I) is an oﬀ-pathway
2587oligomeric form, the appearance of which competes with the
2588transition to the native state.488,489 In vitro unfolding of this
2589protein is a very complex, irreversible process, indicating that
2590the information encoded in its polypeptide chain is not
2591suﬃcient to ensure normal folding. Actin not only cannot fold
2592without chaperons but also cannot form a compact structure
2593without its ligands, the Ca2+ ion, and ATP. Also, it cannot
2594maintain the folded native state without fastening it with the
2595Ca2+ ions. Actin always exists as a part of various complexes.
2596Similar to many other IDPs, actin interacts with an enormous
2597number of partners, acting as a hub protein,476,490 and
2598possesses numerous PTM sites. Many of the actin binding
2599proteins themselves are IDPs involved in various signaling
2600systems and interacting with other hub proteins.
26013.6.2. Intrinsic Disorder in the Extracellular Matrix.
2602The extracellular matrix is another example of semirigid,
2603proteinaceous, scaﬀolding structure that represents a three-
2604dimensional network fulﬁlling structural and biological
2605functions (they contribute to the shape, organization, and
2606mechanical properties, such as tensile strength and resistance to
2607compression, of tissues) and is comprised of multidomain
2608proteins and proteoglycans. Extracellular structural proteins
2609include collagens, the most abundant protein family in the body
2610(∼30% of total protein),491 elastin and associated proteins
2611(ﬁbrillins, ﬁbulins),492 laminins,493 and a ubiquitous extrac-
2612ellular protein, ﬁbronectin.494 Many other proteins termed
2613matricellular proteins, being deposited into the extracellular
2614matrix and bound to structural proteins, do not play a structural
2615role. These proteins (such as thrombospondins, secreted
2616protein acidic, and rich in cysteine, SPARC, osteopontin) act
2617as extracellular “adapters” and modulate cell function.7
2618Comprehensive bioinformatics analysis revealed that, as
2619compared to the complete human proteome, the extracellular
2620proteome is signiﬁcantly enriched in proteins containing more
2621than 50% of disordered residues.495 The characteristic feature
2622of the proteins in extracellular matrix is the presence of long
2623IDPRs. Organization and assembly of the extracellular matrix,
2624development of mineralized tissues, and cell-matrix adhesion
2625are the biological processes overrepresented in the most
2626disordered extracellular proteins. Among important functions
2627ascribed to extracellular disorder are binding to growth factors,
2628glycosaminoglycans, and integrins at the molecular level.495
2629One of the interesting players in the extracellular matrix
2630assembly is elastin, a vertebrate protein responsible for the
2631elastic recoil of arteries, skin, lung alveoli, and uterine
2632tissue.496−498 It was pointed out that the elastic properties of
2633elastin are very similar to the elasticity of an insect elastic
2634protein resilin, which is used by various insects to store elastic
2635energy needed for action of the wing joints of dragonﬂies499
2636and the jumping mechanism of ﬂeas.500 Contrarily to the
2637collagens that typically form a highly ordered, triple helix
2638structure501 possessing 10 times the elastic energy storage
2639capacity of steel,502 the ﬂexible and easily stretched structure of
2640elastin503 is characterized by a signiﬁcant amount of structural
2641disorder.497,504,505 Despite the highly disordered nature of both
2642monomeric elastin and elastin ﬁbrils ﬁbrils, this protein has a
2643half-life of about 74 years,506 being the longest lasting protein in
2644the body.
4. CONCLUDING REMARKS
2645Intrinsic disorder is a versatile feature of large protein
2646complexes. This is a very important observation because a
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2647 multimeric form represents the functional state of many
2648 proteins. Protein intrinsic disorder deﬁnes the ability of the
2649 components of the functional proteinaceous machine to
2650 assemble, move relative to each other, and recognize,
2651 accommodate, and respond to the external regulators. For
2652 doing all of this, the proteinaceous components of the
2653 functional protein complexes have two distinctive types of
2654 disorder: for internal use (assembly and movement) and for the
2655 external applications (interaction with regulators).
2656 Intrinsic disorder is uniquely positioned to serve various
2657 speciﬁc needs of diﬀerent proteinaceous machines. For
2658 example, ATP-dependent proteases are molecular machines
2659 that unfold proteins and walk along tracks consisting of
2660 unfolded polypeptide chains. The proteasome is partially held
2661 together by a disordered protein, and ﬂexible loops are essential
2662 for the ability of adaptor proteins to shuttle substrates to
2663 proteases. Perhaps, then, it is not surprising that these machines
2664 are sensitive to the presence of intrinsic disorder in their
2665 substrates. Indeed, potential substrates that lack IDPRs are
2666 ineﬃciently degraded, suggesting that the protease motor must
2667 grab onto a disordered region to unfold the rest of the protein.
2668 Intrinsic disorder is not suﬃcient, as some intrinsically
2669 disordered sequences with unusual sequence composition
2670 cannot support the application of force against a folded
2671 domain. Understanding the complete role of these intrinsically
2672 disordered sequences, and the balance between the need for
2673 intrinsic disorder and sequence composition, will be critical for
2674 fully understanding how ATP-dependent proteases unfold and
2675 degrade their substrates.
2676 Similar perspectives can be drawn for all of the protein
2677 complexes discussed in this Review. For each of them, disorder
2678 represents a universal tool crucial for the complex formation
2679 and action. Some important mechanisms in complex assembly
2680 (i.e., assembly chain reaction) rely on the intrinsic disorder of
2681 the complex’s parts and their capability for mutual folding.
2682 Besides various versatile roles of intrinsic disorder in assembly,
2683 function, and regulation of diﬀerent proteinaceous machines
2684 discussed in this Review, a new concept of a “stochastic
2685 machine” has been recently proposed as a basic mechanism of a
2686 scaﬀold protein action.507 According to this concept (which was
2687 built based on the analysis of the mechanisms of action of an
2688 intrinsically disordered scaﬀold protein axin that colocalizes β-
2689 catenin, casein kinase Iα, and glycogen synthetase kinase 3β),
2690 interaction of binding partners with long IDPR of the scaﬀold
2691 protein generates a highly dynamic complex comprised of
2692 several structured domains connected by long ﬂexible linkers.
2693 Such ﬂexible colocalization was suggested to dramatically
2694 accelerate chemical interactions between proteins involved in
2695 the complex formation and ensured a unique way of controlling
2696 the complex action via random movements of its parts and not
2697 by coordinated conformational changes.507
2698 In this ﬁeld, as in protein science in general, transition is
2699 happening from considering complexes as semirigid and static
2700 entities to treating them as highly dynamic ensembles. Because
2701 multichain protein complexes are typically characterized by
2702 exceptionally large dimensions, and because they possess both
2703 spatial and temporal structural ﬂexibility and functional disorder
2704 at multiple levels, the analysis of these ensembles is a
2705 challenging task. Therefore, elaboration of novel means for
2706 structural and functional analyses of oligomeric proteins is an
2707 important future direction. Further work is clearly needed for a
2708 deeper understanding of the multifarious roles and functions of
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2896 RanGEF guanine nucleotide exchange factor
2897 RNAPII RNA polymerase II
2898 RNP ribonucleoprotein
2899 ROD reduction of dimensionality
2900 rRNA rRNA
2901 SAMP small ubiquitin-like modiﬁer protein
2902 smFRET single-molecule ﬂuorescence resonance energy
transfer
2903 SNAP-25 synaptosome-associated protein of 25 kDa
2904 SNARE soluble N-ethylmaleimide-sensitive factor attach-
ment protein receptor
2905 snRNA small nuclear RNA




2910 TBP TATA-box binding protein
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